THC BioMed Now Licensed to Sell Edibles, Topicals and Extracts

VANCOUVER, Oct. 24, 2019 /CNW/ – THC BioMed Intl Ltd. (“THC BioMed“) (CSE: THC) announces that Health Canada has amended its licence to authorize the sale of cannabis extracts, topicals and edibles.

The Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year, with edibles representing more than half that amount, according to a report from Deloitte in May 2019. This spending is expected to be in addition to the approximately $6 billion estimated domestic market for recreational and medical cannabis.

While Health Canada has indicated that sale of these newly legalized products will not be made available to the public until at least mid-December, THC has completed renovations of their flagship Acland Road location to enable production of these products. THC BioMed now has a total of 22 strata lots licensed for production.

THC BioMed expects to start building inventory soon and looks forward to being able to provide the same high quality products to customers in extract, topical and edible form.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed.  In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) the Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year and the other market projections from Deloitte’s report will be relized, (b) THC expects to start building inventory soon and looks forward to being able to provide the same high quality products to customers in extract, topical and edible form and (c) THC will be on the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

SOURCE THC BioMed

For further information: President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E: info@thcbiomed.com

Related Links

http://thcbiomed.com/

The post THC BioMed Now Licensed to Sell Edibles, Topicals and Extracts appeared first on CannabisFN.

Xtraction Services Announces Purchase of Shares in the Open Market by Archytas Ventures LLC

Not for Distribution to U.S. Newswire Servicers or For Dissemination in the United States

LOS ANGELES–(BUSINESS WIRE)–Xtraction Services Holding Corp., (“Xtraction Services”, “XS” or the “Company“) (CSE:XS), a fast-growing provider of equipment leasing solutions to owner/operators of cannabis and hemp companies in the United States, is pleased to announce that Archytas Ventures LLC (“Archytas”) (an investment company controlled by David Kivitz, CEO of XS and Antony Radbod, CMO of XS) purchased Common Shares (Subordinate Voting Shares being the listed class of shares) of Xtraction Services in the open market.

As of Wednesday, October 23, 2019, Archytas purchased a total of 274,500 Subordinate Voting Shares at an average price of CAD$0.2068. Assuming all outstanding Proportionate Voting Shares are converted into Subordinate Voting Shares, Archytas’ total ownership in Xtraction Services would be 11,434,075 Subordinate Shares or approximately 24%.

David Kivitz, Chief Executive Officer of XS, commented, “We are committed to building a quality leasing company that provides much needed financial support to the cannabis and hemp industry. We strongly believe in the value of the business and see tremendous growth potential ahead. Our current market capitalization does not appropriately reflect the true value of XS, nor does it take into consideration our future earning potential. Our recent purchase in the open market reinforces our commitment and belief in the viability of the Company.”

About Xtraction Services

Founded in 2017, XS specializes in providing equipment leasing solutions in the United States to owner/operators of cannabis and hemp companies, including cultivators, oil processors, manufacturers, testing laboratories, among others. In addition, XS provides a full range of consulting services including equipment selection and procurement, through its network of preferred vendor partnerships with original equipment manufacturers and equipment distributors. Further, XS also provides a full range of all on-site support services, including staff recruitment, process development, and product formulation. This powerful dynamic provides an end-to-end solution for customers which results in recurring revenues, strong profit margins, and a proven business model for XS stakeholders.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This press release contains “forward-looking information” and may also contain statements that may constitute “forward-looking statements”, collectively “forward-looking information”, within the meaning of applicable Canadian securities legislation. Such forward-looking information is not representative of historical facts or information or current condition, but instead represent the beliefs and expectations regarding future events about the business and the industry and markets in which Xtraction Services operates, as well as plans or objectives of management, many of which, by their nature, are inherently uncertain. Generally, such forward-looking information can be identified by the use of terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information contained herein may include but is not limited to, any additional share purchases by the Archytas including size, price and timing thereof.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements, which are qualified in their entirety by this cautionary statement. Xtraction Services does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

Contacts

Xtraction Services
David Kivitz

Chief Executive Officer

Antony Radbod
Chief Marketing Officer

Tel: 1-407-900-4737 Ext. 5
Email: ir@xtractnow.com
www.xtractnow.com

The post Xtraction Services Announces Purchase of Shares in the Open Market by Archytas Ventures LLC appeared first on CannabisFN.

cbdMD, Inc. Announces Timing of Regular Monthly Dividend for November 2019 for 8.0% Series A Cumulative Convertible Preferred Stock

CHARLOTTE, N.C.

cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, today announced the timing for the payment of its declared regular monthly dividend of $0.0667 per share of its 8.0% Series A Cumulative Convertible Preferred Stock (NYSE American: YCBD PR A) for November 2019. The dividend will be payable on November 15, 2019 to holders of record as of November 1, 2019. The dividend will be paid in cash. The November 2019 dividend is the first dividend declared by us on our 8% Series A Cumulative Convertible Preferred Stock following the issuance of these shares in a firm commitment underwritten public offering which closed on October 16, 2019.

About cbdMD, Inc.

cbdMD, Inc. (NYSE American: YCBD and NYSE American: YCBD PR A) owns and operates the nationally recognized consumer cannabidiol (CBD) brand cdbMD, whose current products include CBD gummies, CBD tinctures, CBD topical, CBD bath bombs, CBD oils and CBD pet products. cbdMD, Inc. is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and CBD pet products. cbdMD is also the proud partner with the Big 3 Basketball League, Barstool Sports, Bellator MMA, (a subsidiary of Viacom: NASDAQ:VIA), LifeTime and Nitro Circus. To learn more about cbdMD, Inc. and our comprehensive line of over 100 SKU’s of U.S. produced, THC-free CBD products, please visit: www.cbdmd.com or follow cbdMD on Instagram and Facebook or visit one of the 3,000 retail outlets that carry cbdMD products.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law. The information which appears on our website and our social media platforms is not part of this press release.

cbdMD, Inc.
Mark S. Elliott, Chief Financial Officer and Chief Operating Officer
(704) 445-3060
mark.elliott@cbdMD.com

The post cbdMD, Inc. Announces Timing of Regular Monthly Dividend for November 2019 for 8.0% Series A Cumulative Convertible Preferred Stock appeared first on CannabisFN.

FluroTech Announces September and Q3 2019 Revenue

CALGARY, Alberta, Oct. 23, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), a technology company focused on the analytical cannabis and hemp testing market, is pleased to announce five unit sales which generated revenue of $116,548 in September, the end of FluroTech’s third quarter of 2019. With the commercialization of the CompleTestTM, the Company continues to ramp up sales efforts through expansion of the sales team, ongoing negotiations with distributors in the United States, and the launch of a referral program with industry participants possessing demonstrated national and international reach.

“I’m pleased with the market acceptance and proof of concept of the CompleTestTM. We have a number of potential sales in the pipeline and expect quarterly growth in sales as numerous strategies are underway which are likely to expand the Company’s market reach and penetration,” stated Danny Dalla-Longa Chief Executive Officer. “New products which allow for further differentiation from competitors of the CompleTestTM are anticipated to be launched in Q4.  We are excited about the future potential of FluroTech.”

Currently, FluroTech’s sales and marketing team is validating the cadmium testing protocol designed by the scientific development team and are preparing for its introduction to the market. The cadmium test is the first of four heavy metal tests which will also include mercury, lead and arsenic.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the benefits to be realized from the Research License, the release of a low THCA testing protocol for hemp and the timing thereof, the release of a cadmium testing protocol and the timing thereof and the benefits of such additional product lines.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTestTM and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, the market for a low THCA testing protocol for hemp and the market for cadmium testing, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology , failure to reach commercialization of the technology, failure to realize the anticipated benefits from the Research License, a lack of demand for low THCA and cadmium testing

The post FluroTech Announces September and Q3 2019 Revenue appeared first on CannabisFN.

Yield Growth Appoints Former Aritzia Director, E-commerce and Online Experience, Karla Cheon, as VP, Marketing

Vancouver, British Columbia–(Newsfile Corp. – October 22, 2019) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that seasoned marketing professional Karla Cheon has been appointed as Vice President, Marketing of Yield Growth, effective October 21, 2019.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/48977_PR-LI_Karlaresized.jpg

Yield Growth Appoints Vice President of Marketing, Karla Cheon.

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6377/48977_PR-LI_Karla.jpg

Cheon has a proven track record as a marketer for successful, growing brands. As a testament to her unique combination of marketing insight, brand-building talent and business acumen, she was selected to lead or partner on the marketing aspects of key strategic growth initiatives at Aritzia during her nearly 15-year tenure at the leading fashion retailer: Aritzia’s expansion into the USA (2007) and Quebec (2013), its eCommerce launch (2012), and its Initial Public Offering (2016). Aritzia is a vertically integrated, innovative design house of exclusive fashion brands. It reported net revenue of $874 million in Fiscal 2019.

In particular, Cheon has deep expertise in eCommerce and digital marketing, two areas of critical importance to the success of any brand. As Marketing Director, Interactive, she developed the content and traffic generation strategy for aritzia.com. Later, as Director, eCommerce Marketing and Online Experience, she was part of the team that built Aritzia’s first eCommerce website and was responsible for creating its award-winning online experience. As part of the IPO team, she also created Aritzia’s first-ever investors website.

“As Yield Growth prepares to launch new brands and expand its existing brands to new markets, Cheon’s marketing prowess will be invaluable,” says Penny White, CEO of Yield Growth.

Cheon holds a Bachelor of Arts degree with a focus on Communication, Culture and Information Technology from Queen’s University. She is eager to apply her marketing know-how in this burgeoning industry.

“As regulations around cannabis-based products come into alignment, there is a tremendous opportunity for brands who can meet both the needs of an increasingly savvy consumer who seeks high-quality, natural products, as well as demonstrate a commitment to acting responsibly,” says Cheon. “Yield’s portfolio is poised to take advantage of this, and I am tremendously excited to be part of shaping these brands.”

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and edible mushroom assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. It owns the cannabis wellness brands Urban Juve, Wright & Well and Jack n Jane. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall. Jack n Jane is launching cannabis products in Canada in 2019. Yield Growth is launching a line of edible mushroom wellness products in 2020.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677

1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages, Jack n Jane and Flourish Mushroom products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48977

Source: Newsfile Corp. (October 22, 2019 – 2:04 AM EDT)

News by QuoteMedia

The post Yield Growth Appoints Former Aritzia Director, E-commerce and Online Experience, Karla Cheon, as VP, Marketing appeared first on CannabisFN.

Benzinga Cannabis Capital Conference Connecting Cannabis Investors & Executives in Chicago

The Benzinga Cannabis Capital Conference will take place at Chicago’s Palmer House on October 22 and 23, 2019. Cannabis investors will have a chance to come face-to-face with cannabis companies to hear about their advancements in the rapidly growing industry, while cannabis executives will have an opportunity to grow their business and attract investors with lightning round presentations and one-on-one meetings.

The conference will feature speakers including:

 

CFN Media Interviewing Mark Krytiuk, President of Nabis Holdings at the Toronto Benzinga Capital Conference 2019

 

CFN Media will provide full coverage of the conference via exclusive interviews with thought leaders and pioneering companies. If you’re company is interested in an interview, please contact Frank Lane at flane@cannabisfn.com or (800) 517-5820 to schedule a time. The coverage will be published on the CFN Media Video Library over the coming weeks.

About the Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America. No other conference offers the level of access and seamlessness of interaction between entrepreneurs building future billion-dollar cannabis enterprises and the investors whose capital will make that happen. 

Individuals or companies interested in attending the conference can buy tickets online at:

https://benzingacannabisconference.com/chicago/ 

About CFN Media

See other upcoming conferences on CannabisFN.com’s conference calendar:

https://www.cannabisfn.com/event-calendar/

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

For Visitors and Viewers 

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies 

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The post Benzinga Cannabis Capital Conference Connecting Cannabis Investors & Executives in Chicago appeared first on CannabisFN.

Tech Guru Steering the Ship for CanIdeal’s Innovative Cannabis B2B Platform; Plus Exclusive Interview with CEO Joseph Farruggia

Does success really breed success? According to researchers at SUNY Stony Brook in a 2014 study, it indeed does. While the study mostly tested the basic principle without merit given for bona fide accomplishments, every company wants to have leadership at the helm with deep experience and a track record of accomplishments. In that case, it would stand to reason that the likelihood of success is further increased from the 9-31% increase the research showed.

Fast forward to 2019 enter the exploding legal cannabis market.

Those that have been involved in the cannabis space for the better part of the last decade, particularly in the last couple years, have seen something pretty amazing happen within the once clandestine industry. With cannabis now legal in 33 U.S. states for medical purposes and 11 states and Canada for recreational use, the market has moved from the back alley to the board room. Many successful businessmen, business women, entrepreneurs, athletes and celebrities have very publicly made the leap into legal cannabis.

Accredited?Click here to see company investor deck

That’s the type of opportunity where skilled business acumen, financial astuteness, experience with new markets and corporate networking skills are worth their weight in gold. We’re talking about the type of opportunity these men and women will never see again in their lifetime and they don’t want to miss out.

How big? Industry-research experts at Arcview Research and partner BDS Analytics see the legal cannabis market (which doesn’t include cannabinoid and related product sales) growing from $3.4 billion in 2014 to $40.6 billion in 2024.

Joseph Farruggia wasn’t going to miss out either and has now brought his skill set to the new cannabis business-to-business platform, CanIdeal.

CanIDeal? Yes You Can.

Joseph Farruggia, CanIdeal’s CEO and President, is an investment industry veteran that founded CanIDeal after several notable successes earlier in his career. His vision was clear: to build the first B2B e-commerce platform serving the entire cannabis industry, bringing together growers, processors, technology accessory makers and distributors into one network to efficiently and legally transact cannabis-related business.

Accredited?Click here to see company investor deck

As Mr. Farruggia told CFN Media in a recent interview at the Cannabis World Congress and Business Expo in Los Angeles, “We have a B2B platform for the entire cannabis industry so that anyone in the industry can ‘come to the party,’ establish a brand and sell on a wholesale level across the country.”

 

 

CanIdeal is a robust solution to the huge problem of the cannabis industry being extremely fragmented because legislative framework underpinned by marijuana being a Schedule I drug at the federal level.

Owing to federal prohibition, states are left to craft their own laws applicable within their borders, all the while understanding that interstate commerce of cannabis isn’t possible and federally insured banks are subject to federal laws when providing banking services to an illicit drug. At the same time, with the passage of the 2018 Farm Bill late last year, hemp – defined as cannabis essentially free of the psychoactive THC (<-0.3%) – became legal at the start of 2019. To wit, cannabidiol (CBD) derived from hemp is open to interstate commerce.

The CanIDeal platform takes all this into account, using geo-fencing to recognize where companies are located. From there, potential supply chain agreements can be presented within the laws of the respective state. Simply, CanIdeal is designed to bridge all the gaps and simplify the byzantine nature of coast-to-coast regulations while simultaneously providing opportunities for companies to sell their products and services at the wholesale level and forge new business relationships. All companies can use the B2B platform for free, with CanIdeal taking a small percentage of each transaction conducted through the system.

Letting buyers buy for free and sellers to list for free is a key differentiator in making the CanIDeal platform neutral and a true open, digital marketplace for companies nationwide, according to Farruggia.

No one else has done this at the scale of CanIDeal.

The Brainchild of Farruggia

Joseph Farruggia is well rounded, to say the least. He has extensive experience in the capital markets and investor relations, serving previously as Director of Sales and Advertising for World Perspective Communications, where he was responsible for the launch and all aspects of Money World Magazine and Money World Investment Conferences. He also honed his Corporate America skills as the Investor Relations Specialist at Atlantic Capital Corp. and Wall Street Marketing Group. In this capacity, Farruggia utilized his network and communication abilities to raise capital for companies listed on national exchanges (i.e. NASDAQ, American Stock Exchange) and international markets by creating demand-side pull.

Accredited?Click here to see company investor deck

Farruggia is an entrepreneur too, pioneering corporate branded Wi-Fi for the restaurant sector. He can stake this claim as a co-founder of Cafe.com, Denny’s (NASDAQ: DENN) Wireless Internet. Serving as VP of Business Development for Café.com, Farruggia negotiated the company’s position as the sole approved wireless internet provider throughout the Denny’s franchise and then through Jack In The Box (NASDAQ: JACK) and Dunkin Donuts (NASDAQ:DNKN) quick-serve restaurants before selling Café.com to then publicly-listed ICOA, Inc.

Moreover, Farruggia co-founded Siddha Flowers, the maker of a line of flower essence products sold in Whole Foods, T.J. Maxx (NYSE: TJX), The Vitamin Shoppe (NYSE: VSI) and Sprouts, amongst other places. Today, the brand has products for teeth and gums, stress, memory and more. On that point, Siddha CEO, Stan Deland, sits on the CanIdeal Board of Advisors.

If that wasn’t enough, he is accomplished with the silver screen. Farruggia was the screenwriter for profitable feature films, including Baby Face Nelson starring Academy Award Winner F. Murray Abraham as Al Capone and C. Thomas Howell as Lester Gillis, better known as “Baby Face Nelson”. He also co-wrote Born Bad with Jeff Yonis, which starred Corey Feldman and James Remar.

As it happens, the genesis of CanIDeal occurred while Farruggia was working as a writer and a producer he was collaborating with, who also was a cannabis broker, heard Farruggia’s B2B idea and explained that no such platform existed. With that, Farruggia got to work and CanIdeal was born.

Farruggia has said that he only intends to serve as chief executive of CanIDeal during the initial launch, which ultimately began in May with a reverse merger that left CanIDeal the surviving entity. Farruggia is on the hunt for an experienced CEO to spearhead growth in the future.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

The post Tech Guru Steering the Ship for CanIdeal’s Innovative Cannabis B2B Platform; Plus Exclusive Interview with CEO Joseph Farruggia appeared first on CannabisFN.

PLUS Products Bolsters Research Expertise with the Addition of Chief Scientific Officer Dr. Ari Mackler

In the newly formed position, Mackler will lead evidenced-based edible cannabis research efforts across the entire PLUS Products portfolio of products

SAN MATEO, Calif., Oct. 21, 2019 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”) today announced the addition of Dr. Ari Mackler as the Company’s Chief Scientific Officer. Dr. Mackler brings 20 years of medical affairs, communications, and research experience in pharmaceutical, healthcare, and consumer goods industries.

Prior to joining PLUS, Mackler was vice president of clinical development for The Wonderful Company, where he led health & wellness initiatives to help establish the business as a global branded products leader. He also held previous positions with the multinational pharmaceutical company Merck & Co, the Almond Board of California, the International Tree Nut Council, the Nutritional Research & Education Foundation, and Stem Cell Resource.

Dr. Mackler’s position at PLUS will allow him to pursue research relationships and clinical trials with academic institutions and private partners in an effort to expand and contribute to consumer understanding of cannabis and the benefits it may provide. He will join an existing team of experts at PLUS that includes Michelin-star sous chefs, chemists, and food manufacturing experts who together have helped develop the number one and two best-selling cannabis products in the California1.

“Dr. Mackler has a long history of helping consumer product companies share a clear and scientifically backed narrative around product benefits. Cannabis is a performance category, and the most successful brands will be those that understand and are able to clearly communicate why their products work. There are few researchers of Dr. Mackler’s caliber in the cannabis industry today, and we believe he will play an invaluable role not only for PLUS, but as a though leader within the industry,” stated Jake Heimark, Co-Founder and CEO.

“I have been intrigued by cannabis for years and saw a huge opportunity to apply my scientific and consumer products background for PLUS to help validate and articulate how their products may help people live better lives,” stated Mackler. “I also believe scientifically-based education is vital to the future of the industry, and PLUS has focused their business processes in a way that ensures science is at the center of their product development DNA.”

(1)  Over the last twelve months by units and dollars of retail sales according to BDS Analytics

Availability

California THC: PLUS cannabis infused edibles are available in over 360 licensed retailers across the state of California.

Nevada THC: PLUS cannabis infused gummies are currently available several Las Vegas dispensaries, including 3 Medmen locations, and are expected to be rolled out to dispensaries across Nevada in the coming weeks.

National Hemp CBD: PLUS recently announced a line of 100% Hemp CBD infused gummies. They are available for purchase at plusproducts.com nationwide.

About PLUS

PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA with 80 employees.

For further information contact:

Jake Heimark
CEO & Co-founder
ir@plusproducts.com

Investors:

Blake Brennan
Director of Investor Relations
Blake@plusproducts.com
Tel +1 213.282.6987

Media:

Bill Harrison
Third Street Media Group
bill@thirdstreetmediagroup.com
Tel +1 213.712.8811

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:
This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (each, a “forward-looking statement”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to, statements relating to: Dr. Mackler’s pursuit of research relationships and clinical trials with academic institutions and private partners; and the expectation that PLUS cannabis infused gummies are expected to be in dispensaries across Nevada in the coming weeks.

These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the success of the Company’s investments, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of the Company’s products, customer experience and retention, the continued development of adult-use sales channels, managements estimation of consumer demand in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete capital projects and facilities improvements, the ability to expand and maintain distribution capabilities, the impact of competition, the ability of the Company to implement initiatives and the possibility for changes in laws, rules, and regulations in the industry. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Primary Logo

The post PLUS Products Bolsters Research Expertise with the Addition of Chief Scientific Officer Dr. Ari Mackler appeared first on CannabisFN.

THC purchases an additional lot in its current Kelowna location

VANCOUVER, Oct. 21, 2019 /PRNewswire/ – THC BioMed Intl Ltd. (“THC” or the “Company“) (CSE: THC) announces that it has purchased, through its subsidiary THC BioMed Ltd., an additional strata lot in the industrial complex in Kelowna it currently occupies.

THC previously announced the purchase of additional strata units in the same building in July, April, March and January of this year and in December, October, and June of 2018. THC purchased this property as a part of its expansion plan due to high demand for its products. The new strata lot will be used for production purposes.

The purchase price was $391,500 plus fees and taxes, for a total of $400,148.82. THC purchased the strata lot for cash and did not require a mortgage.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC.  In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct.  Forward-looking statements contained in this press release are made as of the date of this press release include that (a) THC purchased this property as part of its expansion plan due to high demand for its products, (b) the property will be used for production purposes and (c) THC will be in the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The post THC purchases an additional lot in its current Kelowna location appeared first on CannabisFN.

Zenabis Provides Operations Update for September 2019

VANCOUVER, Oct. 21, 2019 /CNW/ – Zenabis Global Inc. (TSX:ZENA) (“Zenabis” or the “Company“) is pleased to provide an update on its recent facility construction and licensing activities and recent cannabis production results.

Highlights:

  • With respect to production results:
    • Cultivation output in September 2019 was 2,089 kg of dried cannabis, with production at Zenabis Atholville outperforming its revised design capacity by 21.8% (the Performance Ratio1).
    • Cultivation output of 2,089 kg of dried cannabis was 21.2% greater than Zenabis’ revised forecast output (as updated on August 6, 2019) of 1,731 kg of dried cannabis.
  • Zenabis submitted a license amendment application for Zenabis Langley’s existing cultivation license on September 27, 2019 to include additional growing areas totaling 101,300 sq. ft. for Zenabis Langley – Part 2A. Zenabis’ licensed annual production capacity is expected to increase by 39,400 kg to 96,400 kg once this license amendment is approved by Health Canada.
  • Zenabis continues to focus on construction and licensing of Zenabis Langley. Zenabis has revised its construction timelines at Zenabis Langley to split Zenabis Langley – Part 2B into two phases (Zenabis Langley – Part 2B and Zenabis Langley – Part 2C) in order to preserve cashflow given current market conditions and reduce ramp-up risk, among other reasons detailed below. Zenabis expects to submit a license amendment for Part 2B in November 2019 (14,800 kg of licensed annual production capacity). Zenabis expects to submit a license amendment for Part 2C in February 2020 (32,000 kg of licensed annual production capacity) to the extent this is justified by market demand at economic prices. Zenabis’ total annual cultivation capacity is expected to increase to 143,200 kg of dried cannabis on completion of licensing at Zenabis Langley early in the second quarter of 2020.

Andrew Grieve, Chief Executive Officer of Zenabis, stated, “We continued to see strong cultivation results in September, with output exceeding our forecast of 1,731 kg by 21.8%. Our Performance Ratio decreased month over month as a result of the significant number of harvests from newly licensed rooms in the month (five of the 10 harvests). The Performance Ratio for newly licensed rooms harvested in September was 14.2% while the Performance Ratio for rooms that had previously been operated was 30.0%. Although the variety of cultivation approaches and rapid scale-up at Zenabis Atholville continues to cause room by room variance, steady-state yields for each cultivar are expected in the near-term, with general steady-state operations expected at Zenabis Atholville by the end of 2019.

“Since our last update, we increased our licensed annual cultivation capacity to 57,000 kg and submitted a licence application that is expected to increase our licensed annual production capacity by 69%, from 57,000 kg to 96,400 kg,” continued Andrew Grieve, Chief Executive Office of Zenabis. “While the timeline revision for Zenabis Langley will delay achieving full design capacity at the facility, we expect to have 96,400 kg of capacity licensed and operational by the end of 2019 with approval of the Zenabis Langley – Part 2A amendment. By early in the first quarter of 2020, we expect to have 111,200 kg of capacity licensed and operational with the approval of the Zenabis Langley – Part 2B amendment.”

_________________________

1

To better reflect the actual performance of its facilities, the Company reports a Performance Ratio, calculated as follows: after each harvest, Zenabis calculates the dry weight cannabis output for each room (the “Total Output”), taking into account the amount of days in production through a combination of: (1) the amount of flower room days used (including turnaround time) for that room; and (2) the amount of flower-room equivalent days required from other flower rooms in support of that harvest (together the “Effective Flower Room Equivalent Days”). Zenabis then divides the Total Output by the Effective Flower Room Equivalent Days in order to produce the “Effective Yield Per Day” for each room, and then divides the Effective Yield Per Day by the Design Capacity Yield Per Day for each room in order to determine actual performance versus the Design Capacity Yield Per Day (this ratio being the “Performance Ratio”). Zenabis believes that the Performance Ratio will provide investors with the best measure of actual cultivation performance versus Zenabis’ published design capacity. Zenabis intends to update and publish updated design capacities for each of its facilities when a facility has harvested from all its flower rooms (with the update at that time reflecting the most recent performance from each flower room) and again, if required due to significantly different results, when a facility achieves consistent monthly performance at a level that is different from its published Design Capacity.  Zenabis revised its design capacity at Zenabis Atholville upwards by 35% (equal to Zenabis Atholville’s Performance Ratio for the three months ended June 30, 2019) from 34,300 kg per annum to 46,300 kg per annum. Zenabis no longer reports outperformance relative to original design capacity (the kg/day figure utilized to derive the 34,300 kg design capacity).

 

Cannabis Production Summary

In September 2019, Zenabis realized a total harvest weight of 2,089 kg of dried cannabis.

The amount harvested at Zenabis Atholville for the three months ending September 30, 2019 exceeded the revised design capacity of the flower rooms by an average of 25.7%, compared to 23.2% in the three-month period from June 2019 through August 2019. A month-to-month comparison of actual harvests compared with harvest forecast based on revised design capacity between January 2019 and September 2019 for Zenabis Atholville is provided in the table below.

Revised Design Capacity

Performance at Zenabis

Atholville

Jan

2019

Feb

 2019

Mar

 2019

Apr

2019

May

2019

June

2019

July

2019

Aug

2019

Sept

2019

Total

Actual Harvest Weight (kg)

474

480

518

809

908

756

1,238

1,912

2,089

9,184

Revised Design Capacity

Harvest Weight (kg)2

467

643

539

796

895

716

1,097

1,357

1,715

8,225

Difference (kg)

7

(163)

(21)

13

13

40

141

555

374

959

Difference (%) – Revised

“Performance Ratio”

1.5%

(25.3%)

(3.9%)

1.6%

1.5%

5.6%

12.9%

40.9%

21.8%

11.7%

2

The Revised Design Capacity Harvest Weight is based on the “design capacity” yield that Zenabis has disclosed to date.  This figure was derived by converting the actual square footage of flower room space and the forecast canopy for each specific flower room into a kilograms per room per day figure based on Zenabis’ historical yield data at the Zenabis Atholville facility based on the yield performance in the three months ending June 2019 for revised design capacity. The Revised Design Capacity Harvest Weight in the table above is the harvest weight that would have resulted if the Design Capacity Yield Per Day for a room was multiplied by the Effective Flower Room Equivalent Days, as defined under “Performance Ratio”. Zenabis has revised its design capacity at Zenabis Atholville upwards by 35% (equal to Zenabis Atholville’s Performance Ratio for the three months ended June 30, 2019) from 34,300 kg per annum to 46,300 kg per annum. Zenabis no longer reports outperformance relative to original design capacity (the kg/day figure utilized to derive the 34,300 kg original design capacity for Zenabis Atholville)

 

In September 2019, Zenabis completed 10 harvests at Zenabis Atholville. The average Performance Ratio for these harvests was 21.8% relative to the revised design capacity. In September 2019, Zenabis did not complete any harvests at Zenabis Stellarton or Zenabis Langley.

2019 Harvest Forecast – Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1

For its existing licensed facilities of Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1, Zenabis expects to produce approximately 16,7335 kg of dried cannabis from October 2019 through January 2020. Zenabis continues to expect to complete its first harvest from Zenabis Langley in November. Zenabis’ forecast harvest output in November includes 1,650 kg from Zenabis Langley. The following table sets out Zenabis’ estimated aggregate monthly harvests for Zenabis Atholville, Zenabis Stellarton and Zenabis Langley Site A – Part 1 for the remainder of 2019 and January of 2020.

July

2019

Aug

2019

Sept

2019

Oct

2019

Nov

2019

Dec

2019

Jan

2020

Total

Forecast (kg)3

1,212

1,579

1,731

3,758

5,199

4,200

3,576

21,255

Actual (kg)

1,238

1,996

2,089

5,323

3 

This forward-looking estimate of future harvest results is based on the following material assumptions: (1) Zenabis Stellarton and Zenabis Langley Site A – Part 1 operate at their published design capacity on a room by room basis for the cultivation space that is licensed and in cultivation at the forward-looking periods noted; (2) Atholville rooms operate based on the current flower schedule and at revised design capacity (a 35% increase relative to original design capacity); and (3) Cultivation commencement at Zenabis Langley Site A – Part 1 in September 2019.   

 

Zenabis intends to provide a monthly cultivation forecast for Zenabis Langley Site A – Part 2A and Zenabis Langley Site A – Part 2B upon receipt of all cultivation license amendments for these phases.

Cannabis Post-Harvesting and Packaging Discussion

The timeline from harvest to the point at which Zenabis completes a sale of that product ranges from a minimum of three weeks (in the case of a bulk sale to a licensed producer) to more than eight weeks (in the case of soft gel capsules which involve external extraction, processing, filling, packaging and shipment). Zenabis recognizes the revenue from completion of such sales in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.

In August 2019, Zenabis replaced its original packaging equipment (for bud jar filling) at Zenabis Atholville with new packaging equipment intended to achieve output of 30,000 units per day (equivalent to more than 90,000 grams per day at current average volumes per jar). During September 2019, the new packaging equipment was not able to achieve its expected output. Instead average output in September was 6,276 units per day, resulting in completed bud filling of only 517 kg (this excludes pre-roll packaging and bulk packaging). As a result, Zenabis was not able to package, ship and sell all of its product cultivated in August and September that had been destined for provincial counterparties, causing a delay in achieving the Company’s expected revenues. With focused troubleshooting, Zenabis has now achieved primary packaging output of 11,643 units per day, on average, during the 14 days ending October 20, 2019, with a maximum of 22,416 units per day. In addition, Zenabis has moved the original packaging equipment at Zenabis Atholville to Zenabis Stellarton and is in the process of ramping-up packaging at Zenabis Stellarton (bud filling commenced October 10, 2019 and pre-roll packaging commenced September 11, 2019). Zenabis expects that, as of November 2019, the Company will have surplus packaging capacity, and that there will be no further delays in the Company’s ability to package, ship and sell all of the product cultivated at Zenabis Atholville.

Currently, indicative demand from provincial counterparties exceeds forecast supply of both packaged flower and packaged pre-rolls for October 2019 through January of 2020 without further reductions in price. Indicative demand does not necessarily translate into actual demand, as the planning process with provincial counterparties may not result in firm volume indications until two weeks prior to a shipment, with purchase orders at times being finalized within days of shipments. As ramp-up of Zenabis’ facilities and the facilities of competitors occurs, Zenabis expects continued pressure on wholesale pricing to be applied by provincial counterparties.

In September, Zenabis packaged 650 kg of bulk product and shipped 190 kg, with the remainder held over for shipment to bulk counterparties in October to meet prepaid supply agreement commitments. Zenabis packaged 732 kg of flower and pre-rolls for provincial counterparties in September and shipped 462 kg. Zenabis also shipped 174 litres of oil products in September.

Construction and Facility Update

Zenabis Atholville

Now that construction is substantially complete4 at Zenabis Atholville, Zenabis is focused on operational improvements to reduce operating costs (increasing packaging automation, for example), improve post-harvest processing, increase yield, and improve packaging throughput.

Zenabis Langley

The first phase of Zenabis Langley (Zenabis Langley – Part 1) is licensed and operational. Since Zenabis’ August operations update was released, Zenabis has reached substantial completion of Part 2A4 and submitted a cultivation license amendment for this phase.

Zenabis remains focused on converting the remaining portion of Zenabis Langley but has revised its conversion plan for these phases to split Zenabis Langley – Part 2B into two phases (Zenabis Langley – Part 2B and Zenabis Langley – Part 2C). Zenabis has made this revision for the following reasons:

  • Focus on Cashflow Generation. By revising the timeline for the submission of Zenabis Langley’s final two flower rooms (Zenabis Langley – Part 2C), Zenabis expects to be able to reduce cashflow outflows for capital expenditure as Zenabis works to generate positive cashflow from operations.
  • Staggering Operational Ramp-Up. Further staggering the operational ramp-up at Zenabis Langley is expected to reduce the inherent issues that come with ramping up a facility of this size. As is illustrated by the packaging discussion above (regarding ramp-up at Zenabis Atholville), ramp-up challenges are possible in this industry. While Zenabis is focused on ramping up its facilities in a manner where any commercially possible action is taken to mitigate ramp-up risk, Zenabis believes that staggering the ramp-up at Zenabis Langley is in the best interest of the Company.
  • Defer Budget Overages. Zenabis recently identified that it expects to spend the entirety of its estimated amount remaining at Zenabis Langley (as forecast in Zenabis’ MD&A for the period ending June 30, 2019 at $13,700,000) upon completion of Part 2B. As a result, Zenabis expects capital expenditure amounts remaining to spend relating to Part 2C to be budget overages (estimated to be $4,000,000). This overage was driven by increases in equipment costs relating to HVAC equipment and automated tray tables. Zenabis has made the decision to defer this overage expenditure to a time when it can be funded by operating cashflow as opposed to cash on hand.

Zenabis expects this timeline revision to have the following impact on the cumulative capacity submitted for licensing at Zenabis Langley:

Month

Cumulative Capacity

Submitted for Licensing

(Original Timeline)

Cumulative Capacity

Submitted for Licensing

(Revised Timeline)

Difference

October 2019

49,300 kg

49,300 kg

November 2019

96,100 kg

64,100 kg

(32,000 kg)

December 2019

96,100 kg

64,100 kg

(32,000 kg)

January 2020

96,100 kg

64,100 kg

(32,000 kg)

February 2020

96,100 kg

96,100 kg

 

A summary of construction status by phase is provided below:

Phase

Design Capacity

Description

Part 1

9,900 kg

– Licensed and operational

Part 2A

39,400 kg

– Consists of 101,300 sq. ft. of flower room space (two flower rooms)

– Substantially complete

– License amendment submitted in September 2019

Part 2B

14,800 kg

– Consists of 38,000 sq. ft. of flower room space (one flower room)

– HVAC, flooring and shade screen installation is ongoing

– Security equipment and lighting installation is substantially complete

Part 2C

32,000 kg

– Consists of 82,200 sq. ft. of flower room space (two flower rooms) and

122,300 sq. ft. of other operational spaces (includes drying rooms,

packaging rooms, mother space and vegetation space)

– HVAC, flooring and shade screen installation is ongoing

– Security equipment and lighting installation is substantially complete

 

_________________________

4 

Zenabis defines substantial completion as the ability to undertake (subject to licensing) all production activities within the design capacity of the facility.

 

Zenabis Stellarton

On September 6, 2019, Zenabis received a cannabis processing license for Zenabis Stellarton. Zenabis commenced pre-roll production at Zenabis Stellarton during the week of September 9, 2019. Zenabis’ current pre-roll production capacity at Zenabis Stellarton is estimated at ~600 kg of pre-rolls per month. Zenabis intends to achieve output of 1,200 kg of pre-rolls per month at Zenabis Stellarton by November 2019, subject to market demand for pre-rolls.

In addition, as noted above, Zenabis has installed at Zenabis Stellarton the packaging equipment (for bud jar filling) previously used at Zenabis Atholville. Following completion of the ramp-up of this equipment, combined with the new packaging equipment in operation at Zenabis Atholville, Zenabis expects to have excess packaging capacity.

Zenabis Delta

Zenabis is currently in the process of constructing extraction and post-processing capacity, a product development lab, a formulation design lab, and a full ISO certified analytical testing lab at Zenabis Delta. This construction project is expected to be complete in the first half of 2020.

Licensing Update

Zenabis is currently in the process of various licensing applications for Zenabis Delta, Zenabis Langley, Zenabis Stellarton and the Zen Craft Grow program as outlined in the table below:

License Submission

Submission Month

Annual Design Capacity

Zenabis Delta – Analytical Testing

May 2019

N/A

Zen Craft Grow – Grower 1

July 2019

350 kg

Zenabis Langley – Part 2A

September 2019

39,400 kg

Zenabis Stellarton – Sales License

October 20195

N/A

Zenabis Langley – Part 2B

November 20195

14,800 kg

Zenabis Langley – Part 2C

February 20205

32,000 kg

5

Expected submission timeline subject to receipt of prior license or license amendment for each facility

 

Zenabis is currently using Zenabis Pitt Meadows, Zenabis Aldergrove and Zenabis Langley for the Company’s propagation and floral business, as well as hemp cultivation activities. All hemp cultivation at Zenabis Aldergrove that uses greenhouse space is currently not being used by the propagation and floral business, and thus will not have a negative impact on Zenabis’ propagation and floral business. Hemp cultivation will neither interfere with the planned cannabis cultivation activities at Zenabis Langley, nor will it reduce the cannabis cultivation design capacity of Zenabis Langley.

Please view the following link for Zenabis operational update presentation:
https://www.zenabis.com/docs/zenabis-operations.pdf

About Zenabis

Zenabis is a significant Canadian licensed cultivator of medical and recreational cannabis, as well as industrial hemp, and a propagator and cultivator of floral and vegetable products. Zenabis employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta, Aldergrove, Pitt Meadows and Langley, British Columbia; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley, Pitt Meadows and Aldergrove provides Zenabis with 3.5 million square feet of facility space that can, if fully converted, be dedicated to cannabis production.

If all facility space at Zenabis Atholville, Zenabis Stellarton and Zenabis Langley is fully converted and dedicated to production, Zenabis will own, and have access to 635,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse cannabis production space at its Langley facility, with this production strategically positioned on Canada’s coasts. Zenabis expects these facilities to have an annual design capacity of 143,200 kg of dried cannabis under its existing capital plan. These facilities, if fully built out and converted for cannabis production, would have an annual design capacity to yield approximately 490,800 kg of dried cannabis annually, for both national and international market distribution. An additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business and produce industrial hemp, and can be converted to cannabis production at such a time that is beneficial to the strategic position of the Company. The Zenabis brand name is used in the cannabis medical market, while the Namaste and Blazery brand names are used in the cannabis adult-use recreational market, and the True Büch brand name is used for Zenabis’ kombucha products.

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the projected kilogram yield of licensed facility space and facility space in the process of, or scheduled for, construction and/or licensing; our expectations for future harvests; the expected timing and completion of current and planned conversion, expansion and optimization of our facilities, including Zenabis Atholville and Zenabis Langley; our expected budget for capital expenditures related to the conversion, expansion and optimization of our facilities, including Zenabis Atholville and Zenabis Langley; our plans for Zenabis Delta; the expected submissions of license amendment applications and site evidence packages; the licensing of our facilities and projected timing thereof; our expectations for our extraction projects, equipment and capacity; our expectations for processing output; our expectations regarding our packaging equipment; the timelines projected for the commencement of cultivation at Zenabis Langley; the effect of hemp cultivation on our cannabis cultivation abilities; and the expected content of future operational updates. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis’ control. These risks, uncertainties and assumptions include, but are not limited to, those described in the shelf prospectus dated April 9, 2019, a copy of which is available on SEDAR at www.sedar.com and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

View original content: http://www.newswire.ca/en/releases/archive/October2019/21/c8207.html

Media Relations: Email: media@zenabis.com, Phone: 1-855-936-2247; Investor Relations: E-mail: invest@zenabis.com, Phone: 1-855-936-2247Copyright CNW Group 2019

The post Zenabis Provides Operations Update for September 2019 appeared first on CannabisFN.

THC BioMed Submits Application to Add Sales of Edibles, Topicals and Extracts to Licence

THC.CSE                                                               THCBF.OTC                                                                                  TFHC.F
Vancouver, BC – (October 17, 2019)

THC BioMed Intl Ltd. (“THC BioMed”) (CSE: THC) announces that is has submitted its application to Health Canada to amended its licence to add sales of cannabis edibles, topicals and extracts.
“THC BioMed has always been focused on producing quality products and we are entering the segment of cannabis edibles, topicals and extracts with the same approach,” said John Miller, CEO of THC BioMed.

The Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year, with edibles representing more than half that amount, according to a report from Deloitte. This spending is expected to be in addition to the approximately $6- billion estimated domestic market for recreational and medical cannabis.
Deloitte estimates that roughly $1.6 billion will be spent on edibles per year in Canada, followed by cannabis-infused beverages at $529 million and topicals at $174 million. Spending on concentrates is expected to hit $140 million, followed by tinctures at $116 million and capsules at $114 million.

In its report, entitled “Nurturing new growth,” released in May 2019, Deloitte states that its view is that edibles will prove to be a more successful segment in Canada, in part because the Canadian market is currently more scalable than the U.S. market. The report states that edibles will “make cannabis more accessible to a wider group of Canadians, many of whom will appreciate edibles’ discreetness and lack of surrounding stigma.”

While the sale of cannabis edibles, topicals and extracts will be legal in Canada for those with the required licences and approvals. Health Canada has indicated that cannabis products will not be made available to the public for purchase until at least mid-December 2019. The regulations place a limit of 10 milligrams of THC per discrete unit for edibles and extracts, while 1,000 milligrams per package for cannabis topicals will be permitted. The product’s packaging must be plain and child-resistant, and display the standardized cannabis symbols along with a health warning message. In order to prevent food-borne illness and cross-contamination, the production of food and cannabis must be done in completely separate facilities.

For specific cannabis edible, topical or extract products, THC will submit applications for product approvals to Health Canada and be subject to the 60-day notice period for new cannabis products becoming available for sale, pursuant to Appendix I of Canada’s updated Cannabis Licence Management Guide. There is a lot of excitement about cannabis edibles, topicals and extracts hitting the market in December. THC BioMed reminds everyone to start low and go slow.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available.
www.thcbiomed.com

President and CEO:
John Miller
THC Biomed Intl Ltd.
T: 1-844-THCMEDS
E: info@thcbiomed.com

Forward-LookingInformation:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed. Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forwardlooking information because THC BioMed can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) Health Canada will amended its licence to add sales of cannabis edibles, topicals and extracts, (b) The Canadian market for cannabis edibles, topicals and extracts is worth an estimated $2.7 billion per year and the other market projections from Deloitte’s report will be realized, (c) THC BioMed will submit any new product approval requests for any specific cannabis edible, topical or extract products, and (c) THC will be on the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

The post THC BioMed Submits Application to Add Sales of Edibles, Topicals and Extracts to Licence appeared first on CannabisFN.

Isracann Biosciences Announces Listing on the CSE and Investor Relations Agreements

VANCOUVER, British Columbia, Oct. 16, 2019 (GLOBE NEWSWIRE) — Isracann Biosciences Inc.  (CSE: IPOT) formerly Atlas Blockchain Group Inc. (CSE: AKE) (XFRA: A49) (OTCPINK: ATLEF) (the “Company”) is pleased to announce the fulfillment of all conditions of its reverse takeover transaction and that the Company has met all conditions to list on the Canadian Securities Exchange. The Company will commence trading at market open on October 17, 2019.

Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. For more information visit: www.isracann.com.

The Company also announces that it has entered into contractual agreements for marketing, communication, shareholder engagement and social media communications. The marketing and communication program will include certain investor relations activities and is designed to provide improved visibility in the Company’s current and planned operations. The Company has entered into agreements with the following service providers: CFN Media, Stonebridge Partners, Investing News Network, Business Television (BTV), Equity Guru, BlackX Management, Mountain Capital, and Invictus IR.

ON BEHALF OF THE BOARD OF DIRECTORS

“Darryl Jones”

Darryl Jones
Chief Executive Officer and President

The CSE does not accept responsibility for the adequacy or accuracy of this release.

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission, and the Alberta Securities Commission.

Contact
Investor Relations
+1(604) 343-8661
info@isracann.com
www.isracann.com

The post Isracann Biosciences Announces Listing on the CSE and Investor Relations Agreements appeared first on CannabisFN.

Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense

MONTREAL, Oct. 17, 2019 (GLOBE NEWSWIRE) — Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly- owned subsidiary, Biocannabix (“BCX”), has executed an Agreement (the “Agreement”) to acquire 100% of the shares of Weedsense Inc. (“Weedsense”), a late stage applicant for a Standard Processing and Medical Sales license under the Cannabis Act, for an aggregate purchase price of $2,000,000 subject to the achievement of certain milestones.

Weedsense is a Montreal- based business that will build a wholesale and distribution facility outside of the downtown core. Weedsense will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and will be distributing cannabis and cannabis-derived products directly to medical patients.

Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”). Excess capacity at the facility may be rented out once fully licensed, and Weedsense can and may act as a secured storage facility or third party logistics (“3PL”) partner for other market participants who seek direct access to the Quebec market who are in need compliant storage or pick/pack solutions.

Weedsense has applied for a Standard Processing and a Medical Sales license under the Cannabis Act through Health Canada and has since received a positive Status Update to build the project. The facility will be built out to EU GMP standards and will seek EU GMP certification in the near future.

Dave Shepard, CEO and Co-Founder of Weedsense Inc. stated: “We began the transactional process with Relevium in May for a direct investment and, through the last few months, both parties concluded that a full acquisition was the most beneficial avenue for generating shareholder value as well as executing on the buildup of the Weedsense facility.”

Sasha Asgary, COO and Co-Founder of Weedsense stated: “The intended purpose of Weedsense is to solve some of the major supply chain issues that are prevalent in the cannabis market today which include getting products to the medical and recreational markets.” Mr. Asgary continued: “With Cannabis 2.0 coming into effect today, the already fragmented upstream will be further complicated by a host of new suppliers of derivative products nationwide. We think that, in collaboration with Relevium, Weedsense will be in a position to offer a superior user experience to all potential customer and client verticals be it on a D2C or B2B basis or as a service provider within the industry.”

Aurelio Useche, CEO of Relevium stated: “The acquisition of Weedsense is an important milestone for Relevium and Biocannabix as the acquisition of this late stage applicant will help us accelerate our path in distributing cannabis products within our home market in Canada.” Mr. Useche further stated: “Once the Weedsense facility receives approval from Health Canada, we will be able to hold inventory and distribute any products regulated under the Cannabis Act most notable of which will be the CannakidsTM products. This will be the beginning of generating significant Canadian revenues under Biocannabix. We are thrilled to have executed this agreement and look forward to working with Dave and Sasha on building out the facility and building up the business.”

Transaction Structure

The aggregate purchase price (the “Purchase Price”) payable by Relevium (the “Purchaser”) to Weedsense (the “Vendor”) is $2,000,000, payable in four performance-based installments.

Upon the execution of the Agreement, Relevium will make an initial payment of $500,000 of the Purchase Price (the “Initial Deposit Amount”) by issuing and delivering an aggregate of 7,142,857 Purchaser Shares.

Subsequent to the Initial Payment, Purchaser will pay the balance of the Purchase Price as follows:

  1. On the day of submission of the Site Video Evidence Package to Health Canada, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Second Deposit Amount”);
  2. On the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay an additional $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (the “Third Deposit Amount”); and
  3. Upon the earlier of (i) the first sale of any cannabis product by the Vendor to any customer, which may include any distributor, wholesaler, retailer or other consumer of cannabis products (the “Date of Commercialization”) and (ii) the first anniversary of the date of the grant of the Cannabis License to the Vendor, the Purchaser shall pay the final $500,000 of the Purchase Price in cash or shares by issuing and delivering an aggregate of 7,142,857 Purchaser Shares (at the election of the Vendors).

Within 30 days following the first 12 months of operations of Weedsense commencing on the Date of Commercialization, the Purchaser shall cause the Vendor to prepare an accounting of its gross sales during such 12 month period, prepared in accordance with Canadian generally accepted accounting principles applicable to private enterprises (the “Statement of Sales”). Within two Business Days after the preparation of the Statement of Sales, the Purchaser shall deliver the Statement of Sales, and all related supporting and background documentation, to the Vendors. If the gross sales as shown on the Statement of Sales is equal to or greater than $1,250,000.00, the Purchaser shall pay an aggregate of $250,000 in cash.

On the date of the Agreement, the Purchaser shall pay to the Vendor the amount of $10,000 in immediately available funds for the purposes of funding the Vendor’s operating expenses. Commencing in the first month following the date of this Agreement, and continuing through to and including February 2020, the Purchaser shall pay to the Vendor $5,000 per month for the purposes of funding the Vendor’s operating expenses.

By no later than March 1, 2020, the Purchaser shall pay to the Vendor, the amount of $750,000 in immediately available funds for the purposes of funding the build-out of the Facility, including leasehold improvements and other modifications to the Facility, in order for the Vendor to seek to obtain the Cannabis License (the “Facility Build-Out Funds”).

By no later than May 31, 2020, the Vendor shall use its commercially reasonable efforts to submit a Site Video Evidence Package to Health Canada in support of the application for the Cannabis License and thereafter shall use its commercially reasonable efforts to diligently pursue the issuance of the Cannabis License from Health Canada.

The Transaction contemplated in the Agreement will close once the Vendor shall have obtained the Cannabis License from Health Canada and all payments necessary will have been delivered by the Purchaser.

The transaction is subject to regulatory approvals including TSX venture Exchange.

About Weedsense Inc.

Weedsense Inc. is a Montreal (Canada) based business that is seeking to build a wholesale and distribution facility outside of the downtown core.

Weedsense will not be cultivating any cannabis at its facility. The Company will be purchasing wholesale or bulk products from other Health Canada licensed producers or processors and distributing directly to medical patients. Patients in the Montreal Metro area may enjoy same day delivery and national clients will enjoy national standard delivery times.

Weedsense may also service the recreational market by acting as a distributor to Provincially sanctioned wholesalers such as the Ontario Cannabis Store (“OCS”) or Société Québécoise du Cannabis (“SQDC”).

Excess capacity at the facility may be rented out. Weedsense can and may act as a secured storage facility or third-party logistics (3PL) partner for other market participants who seek direct access to the Quebec market, need compliant storage or pick/pack solutions.

Weedsense has applied for a Standard Processing and a Medical Sales licenses through Health Canada and has received a positive Status Update to build. The facility will be built out to EU GMP standards.

About Relevium Technologies

Relevium is a publicly traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operation of brands and businesses in the health and wellness markets and medical cannabis. The Company pursues its business strategy through an acquisition and partnership model in a holistic approach to encompass a wide range of health and wellness consumer products. Relevium operates through two wholly owned subsidiaries:

BGX E-Health LLC (BGX), based in Orlando, Florida, markets dietary supplements, nutraceuticals, sports nutrition and cosmeceuticals primarily through its Bioganix® brand portfolio in the US and Europe. Relevium’s premium brands are sold at some of the world’s largest retailers including Walmart.com and Amazon.com.

Biocannabix Health Corporation (BCX), based in Montreal, Quebec, is a biopharma nutraceutical company focused on delivering pediatric endo-medicinal nutraceuticals for cannabinoid therapy.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and United States securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified using forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, or “would” occur.  Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek to rely on the applicable safe harbor.

On Behalf of the Board of Directors

RELEVIUM TECHNOLOGIES INC.

Aurelio Useche
President and CEO

For more information about this press release:

Tel: +1.888.528.8687

RELEVIUM TECHNOLOGIES INC
Email: investors@releviumcorp.com
Website: www.releviumtechnologies.com

Primary Logo

 

Source: GlobeNewswire (October 17, 2019 – 8:30 AM EDT)

News by QuoteMedia

The post Relevium Acquires 100% of Late Stage Processing and Medical Sales Applicant Weedsense appeared first on CannabisFN.

The Alkaline Water Company Extends the Alkaline88® Brand with Best-in-Class Topical CBD Products

  • Alkaline88® will be taking orders for its CBD products at the upcoming ECRM CBD Food and Beverage Program on November 4-6, 2019 in Cape Coral, Florida.
  • Full-scale delivery of topical products expected to begin in January, 2020.

SCOTTSDALE, Ariz., Oct. 17, 2019 (GLOBE NEWSWIRE) — The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) (the “Company”), a producer of premium bottled alkaline drinking water and flavored water sold under the brand name Alkaline88®, is pleased to announce the formation of A88 Infused Products Inc., a wholly-owned Nevada corporation (“A88 Infused Products”). A88 Infused Products has developed a variety of topical CBD infused products which include salves, balms, lotions, essential oils, and bath-salts all made with lab-tested full-spectrum hemp.

“We now view the entire CBD market as a tremendous opportunity to further expand our brand and product portfolio in both the ingestibles and the natural beauty and personal care category within the much larger health and wellness space. We believe that our growing national footprint consisting of convenience stores, supermarkets, drug stores, and retailers provide us a unique opportunity to take advantage of this significant emerging market trend. We have already been in discussions with a number of our major retail clients who have been early adopters and are excited about this product expansion,” stated Richard A. Wright, president and chief executive officer of The Alkaline Water Company, Inc.

BDS Analytics estimates that U.S. sales of cannabis and hemp-derived CBD product is expected to surge from $1.9 billion in 2018 to $20 billion by 2024, a compound annual growth rate of 49%. According to their research, there is substantial consumer interest in the consumables (tinctures, pills, beverages, food) and Topicals (creams, balms, salves) formats, despite the current low consumer penetration rate. In addition, many major national retailers (CVS, Walgreens, Rite Aid, Sprouts, Whole Foods, Ulta, GNC Holdings, Designer Brands, Urban Outfitters, and Neiman Marcus) have been early adopters of CBD topical products and have introduced various product lines in select markets.

Wright further added, “Our recent introduction of CBD ingestibles has generated strong interest from our major U.S. retail clients. This speaks highly of the brand integrity we have built with our flagship product, Alkaline88®. We knew CBD topicals was the next natural extension for the Alkaline88® brand based on the product specific knowledge we acquired from working with Centuria Foods Inc. Over the past several months, we have teamed up with one of the foremost developer and manufacturer of high-performance and authentically natural beauty and personal care products. This established partner has been behind the scenes of many of the world’s most successful, natural, organic, and CBD brands, ranging from Food/Drug/Mass to ultra-premium.”

New Alkaline88® topical products developed with lab-tested full-spectrum hemp include:

  • CBD infused Soothing Salve – 100% natural calming CBD muscle salve infused with luxurious oils and butters to help soothe and comfort irritated, sore muscles.
  • CBD infused Lip Balm – 100% natural, made with coconut oil and cocoa butter, ingredients work to moisturize and hydrate lips for all-day comfort.
  • CBD infused Hydrating Body Lotion – 100% vegan and cruelty-free body lotion for all skin types packed with shea butter and aloe vera to moisturize, hydrate, and soothe skin for all-day comfort.
  • CBD infused Hydrating Hand Lotion – 100% vegan and cruelty-free, this rich nutrient-dense hand and foot cream contain whipped shea Butter and luxurious oils and extracts, which help to deeply nourish and moisturize hands and feet, leaving them soft and supple.
  • CBD infused Essential Oil Roller – 100% natural, vegan, and cruelty-free ready for use, concentrated blend of 100% pure essential oils, perfectly balanced with fractionated coconut oil.
  • CBD infused Bath Salts – 100% vegan and cruelty-free bath salt formula combines the therapeutic properties of Epsom salts and rejuvenating menthol and essential oils, for the ultimate relaxing experience.

Photos of the new CBD infused product line can be viewed here:
https://www.globenewswire.com/NewsRoom/AttachmentNg/193df781-fae2-4786-abae-0e04794fc4e6
https://www.globenewswire.com/NewsRoom/AttachmentNg/39701105-1579-4776-a3f5-0d6511701002

The Company intends to comply in full with all federal, state, and local laws, rules and regulations as the Company develops its CBD-infused products. The Company will not pursue the commercial production or sale of CBD-infused products until legally permitted. The Company is closely watching and responding to all regulatory developments within the FDA and in each individual U.S. state, and plans to launch its CBD infused products accordingly.

About Centuria Foods Inc. 

Since 2014, Centuria Foods has been producing the safest, highest quality CBD oil in the industry. Prior to the legalization of Hemp and CBD production via the industry-changing 2018 Farm Bill, Centuria Foods was the only legal CBD producer in the U.S., having approvals from the Department of Homeland Security, as well as the Customs and Border Protection. Centuria remains at the forefront of the CBD industry as it continues its meteoric growth under the legal framework of the 2018 Farm Bill. For more information on Centuria visit https://centuriafoods.com/

About The Alkaline Water Company Inc.

The Alkaline Water Company Inc. (NASDAQ and TSXV: WTER) is a leading producer of premium bottled alkaline drinking and flavored water sold under the brand name Alkaline88®. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes. The Company recently announced a broad line of CBD infused products which include ingestibles and topical products. For its ingestibles line, the A88 Infused Beverage Division Inc. produces CBD infused drinks, beverage shots, tinctures, capsules, and powder packs. For its topicals line, A88 Infused Products Inc. produces salves, balms, lotions, essential oils, and bath-salt all made with lab-tested full-spectrum hemp. The Alkaline Water Company Inc. is currently pursuing a national multi-channel, mass-market expansion strategy with a direct-to-warehouse model and co-packaging facilities that are strategically located 600 miles within 95% of the U.S. population. Founded in 2012, the Company is headquartered in Scottsdale, Arizona. To learn more about The Alkaline Water Company, please visit www.thealkalinewaterco.com or connect on Facebook, Twitter, Instagram or LinkedIn.

Notice Regarding Forward-Looking Statements

This news release contains “forward-looking statements.” Statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the following: the statement relating to taking orders for the Company’s CBD products at the upcoming ECRM CBD Food and Beverage Program on November 4-6, 2019 in Cape Coral, Florida; the statement that full-scale delivery of topical products expected to begin in January, 2020; the statement that the entire CBD Market is a tremendous opportunity to further expand the Company’s brand and product portfolio in both the ingestibles and the natural beauty and personal care category within the much larger health and wellness space; the Company’s belief that the Company’s growing national footprint consisting of convenience stores, supermarkets, drug stores, and retailers provides the Company a unique opportunity to take advantage of the significant emerging market trend relating to the CBD market; and that BDS Analytics estimates that U.S. sales of cannabis and hemp-derived CBD product is expected to surge from $1.9 billion in 2018 to $20 billion by 2024, a compound annual growth rate of 49%.

The material assumptions supporting these forward-looking statements include, among others, that the demand for the Company’s products will continue to significantly grow; that the past production capacity of the Company’s co-packing facilities can be maintained or increased; that the Company will receive all necessary regulatory approvals for the production and sale of CBD-infused products; that there will be increased production capacity through implementation of new production facilities, new co-packers and new technology; that there will be an increase in number of products available for sale to retailers and consumers; that there will be an expansion in geographical areas by national retailers carrying the Company’s products; that there will be an expansion into new national and regional grocery retailers; that there will be an expansion into new e-commerce, home delivery, convenience, and healthy food channels; that there will not be interruptions on production of the Company’s products; that there will not be a recall of products due to unintended contamination or other adverse events relating to the Company’s products; and that the Company will be able to obtain additional capital to meet the Company’s growing demand and satisfy the capital expenditure requirements needed to increase production and support sales activity. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, governmental regulations being implemented regarding the production and sale of alkaline water or any other products, including products containing hemp/CBD; the fact that consumers may not embrace and purchase any of the Company’s CBD-infused products; the fact that the Company may not be permitted by the FDA or other regulatory authority to market or sell any of its CBD-infused products; additional competitors selling alkaline water and enhanced water products in bulk containers reducing the Company’s sales; the fact that the Company does not own or operate any of its production facilities and that co-packers may not renew current agreements and/or not satisfy increased production quotas; the fact that the Company has a limited number of suppliers of its unique bulk bottles; the potential for supply-chain interruption due to factors beyond the Company’s control; the fact that there may be a recall of products due to unintended contamination; the inherent uncertainties associated with operating as an early stage company; changes in customer demand and the fact that consumers may not embrace enhanced water products as expected or at all; the extent to which the Company is successful in gaining new long-term relationships with new retailers and retaining existing relationships with retailers; the Company’s ability to raise the additional funding that it will need to continue to pursue its business, planned capital expansion and sales activity; and competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States and Canada. Although the Company believes that any beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Readers should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents the Company files with the SEC, available at www.sec.gov, and on the SEDAR, available at www.sedar.com.

The Alkaline Water Company Inc.

Richard A. Wright
President and CEO
800-923-1910
investors@thealkalinewaterco.com

Media

Jessica Starman
888-461-2233
jessica@elev8newmedia.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Primary Logo

Alkaline88 CBD Product Portfolio – Topicals and Ingestibles
The Alkaline Water Company
Alkaline88 CBD Topicals Product Portfolio
The Alkaline Water Company

 

Source: GlobeNewswire (October 17, 2019 – 8:00 AM EDT)

News by QuoteMedia

The post The Alkaline Water Company Extends the Alkaline88® Brand with Best-in-Class Topical CBD Products appeared first on CannabisFN.

YIELD GROWTH Signs Letter of Intent with Apothecary Botanicals to Manufacture and Distribute Yield’s New Line of Cannabis-Infused Topicals, Jack n Jane, in Canada

Vancouver, British Columbia–(Newsfile Corp. – October 17, 2019) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that it has signed a non-binding letter of intent to enter into a co-packing agreement with Apothecary Botanicals, a Canadian licensed cannabis producer and subsidiary of Geyser Brands Inc. (TSXV: GYSR), for the production and launch of Yield Growth’s Canadian Cannabis brand Jack n Jane, a line of cannabis-infused products including tinctures, topicals and capsules.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/48846_yield1.jpg

Jack n Jane is Yield Growth’s New Line of Cannabis-Infused Topicals

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6377/48846_yield2.jpg

This announcement coincides with Health Canada’s official legalization of the production and sale of cannabis extracts and cannabis topicals effective today, marking the one-year anniversary of the legalization of recreational marijuana in Canada.

Yield Growth will engage Apothecary Botanicals to manufacture and distribute its Jack n Jane products in British Columbia, combining Yield Growth’s proprietary formulations with Apothecary Botanicals’ cannabis supply, services, facilities, equipment and required Health Canada licenses for processing and sales. Yield Growth will supply all non-cannabis ingredients, packaging, and design while Apothecary Botanicals will supply cannabis containing THC and/or CBD as required for the various product formulations. The first phase of production is expected to include three tinctures containing THC and CBD, with a goal of coming to market by December 31, 2019.

Yield Growth intends to incorporate many of the products in its catalogue into the Jack n Jane line, including its own proprietary hemp root oil as a key ingredient and many other high-quality botanicals. The product line currently includes CBD and THC tinctures, muscle and joint gel, massage oils, muscle balm, and foot cream, with several new products in development including transdermal patches and bath soaks.

“Ancient Ayurveda apothecaries worked diligently over millennia to unlock the vast potential of this medicinal plant,” says Penny White, CEO of Yield Growth. “We are looking forward to bringing the highest quality skin care and personal care products to Canada with an LP in our beautiful home city of Vancouver.”

David Eto, CEO of Apothecary Botanicals, commented, “We are pleased to offer our services to Yield Growth. Our co-packing and manufacturing capabilities combined with our Health Canada approved Licensed Production Facility will support Yield Growth’s goal of entering the Canadian market.”

According to a report by Deloitte, “edibles, topicals and infused beverages are poised to be the hot new cannabis products.” Deloitte estimates that the Canadian market for edibles and alternative cannabis products to be worth C$2.7 billion annually. The report states that 53% of surveyed likely Canadian cannabis consumers are eager to try topicals.

About Geyser Brands Inc.
 

Geyser Brands Inc. (TSXV: GYSR) is a consumer health and wellness company operating within the Canadian cannabis industry. Geyser’s proprietary delivery technologies include all natural nano-technology, slow-release mechanisms, and non-molecule degrading baking processes. The company provides expertise from conceptual innovation to manufacturing and end-use distribution. Geyser owns a suite of several brands within the consumer-packaged goods market that are offered nationwide at many recognized retailers. Geyser Brands owns a Health Canada approved Licensed Production Facility and operates 15,000 sqft of manufacturing space in two GMP facilities near Vancouver, BC. For more information, visit www.geyserbrands.com.

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and edible mushroom assets and owns wellness brands Urban Juve, Wright & Well, Jack n Jane and Flourish Mushrooms. It has a catalogue of over 200 proprietary beauty, wellness, edibles and beverage formulas at various stages of commercialization. It has filed 12 patents to protect its extraction method and formulas. Urban Juve hemp powered skin care products have been featured in British Vogue, Vanity Fair UK and Elle Canada and Urban Juve has an alliance with leading online beauty community, ipsy. Wright & Well is launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall. Yield Growth plans to launch a line of edible mushroom wellness products in 2020. Yield Growth is building international distribution channels and has multiple revenue streams including services, licensing and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.Investor Relations Contacts:

Penny White, President & CEO
Kristina Pillon, Investor Relations
invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages, Jack n Jane and Flourish Mushroom products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48846

Source: Newsfile Corp. (October 17, 2019 – 2:04 AM EDT)

News by QuoteMedia

The post YIELD GROWTH Signs Letter of Intent with Apothecary Botanicals to Manufacture and Distribute Yield’s New Line of Cannabis-Infused Topicals, Jack n Jane, in Canada appeared first on CannabisFN.

SinglePoint Heating Up with New Cannabis Cigarette Launch

There has been plenty of media coverage lately on e-cigarettes and vaping products, including restrictive regulation and flat-out bans on vape and nicotine products, spurred on by a series of mysterious deaths most attribute to black market products. Hidden underneath the legislation is the underlying fact that millions of people like to smoke and, according to some experts, outlawing said products is simply not going to work. It will just drive people back to smoking combustible cigarettes.

Against this backdrop, SinglePoint (OTCQB: SING) is banking on the trend for alternatives to cigarettes remaining strong, coupled with the growing awareness about hemp products. Judging by the reaction to the company’s new Pure American Hemp cigarettes launched this month at the 2019 National Association of Convenience Stores show (NACS) in Atlanta, management is charting the right course.

Click here to see the company corporate presentation

History Repeats

SinglePoint CEO Greg Lambrecht has a track record for knowing what will sell in America and how to capitalize on it. The SinglePoint chief executive has particular experience in the tobacco space, successfully launching Premium Cigars International with an emphasis on expansion through convenience stores.

Starting with one c-store, Lambrecht ultimately placed his company’s cigars in tens of thousands of locations and brought the company public on the Nasdaq exchange.

Lambrecht is following the same playbook for an even bigger market with hemp, a form of cannabis sativa that doesn’t contain (or negligible amount of <0.3% by law) THC (tetrahydrocannabinol), the component of marijuana that is responsible for the psychoactive effect commonly associated with the plant. Notably, hemp contains cannabidiol (CBD), the cannabis compound widely heralded for its medicinal benefits, including reducing anxiety, which makes it ideal as an alternative to traditional cigarettes. Equally important, hemp doesn’t contain nicotine or tobacco, which can be useful in helping people wean themselves off conventional cigarettes.

Hemp became legal nationwide in the U.S. at the start of 2019 with the passage of the 2018 Farm Bill in December, opening up roadways for interstate commerce.

Click here to see the company corporate presentation

Following the recipe for Lambrecht’s past success with cigars, the new pre-rolls (that’s the official word for hemp cigarettes) were on display at NACS this month. With scores of people wanting to check out the new smokes, Lambrecht commented, “It reminded me of the successful product introduction of Premium Cigars International and PrimeTime™ to the convenience store industry.”

Consumers Open Pocketbooks

The cannabis/hemp marketplace is emerging rapidly. The industry insight group Arcview Market Research and its partner BDS Analytics forecast that CBD sales in the U.S. will exceed $20 billion by 2024. While a bit more conservative, Cowen & Co. see CBD sales of $15 billion by 2025, figures that speak to the lucrative market that SinglePoint is addressing. Smokable hemp products are one of the fastest growing market segments, expanding by 250% from 2017 to 2018, according to the cannabis market research firm Brightfield Group.

To put the opportunity in perspective, consider that Grandview Research says the global cigar and cigarillo market size was valued at $16.99 billion in 2018.

As the cannabis/hemp marketplace matures, a price segmentation is occurring, with it becoming evident that consumers are willing to pay-up for premium products. According to Brightfield Group, a 2016 survey showed that more than one-third of cannabis users are willing to pay more for organic products. Another study by Brightfield in 2017 affirmed that the trend towards high-end product remains strong.

Furthermore, a 2018 study showed that consumers believe that cannabis products sold legally is superior to that sold illicitly. All of this data bodes well for SinglePoint launching its new hemp pre-rolls.

The Pure American Hemp pre-rolls are available in original and menthol in packs of 20 for $19.95. The products are aligned with consumer demand, being organically grown and made of 100% nicotine and tobacco-free hand-selected plants from U.S. family farms.

Click here to see the company corporate presentation

 

Cash Register Already Ringing

Speaking about the response to showcasing the Pure American Hemp product at NACS, Lambrecht summed it up in saying that the success “was beyond what anybody in our group imagined.” He added “It truly gave us deep insight to how large of an opportunity this is.”

NACS was a premier event to roll-out the product. SinglePoint prepped for the convention with a marketing blitz beforehand introducing the pre-rolls to thousands of buyers at convenience stores around the country. SinglePoint says there is interest from parties representing over 20,000 retail locations already as it taps into a market comprised of in excess of 150,000 c-stores. The company says it has already received “multiple” orders and will be following up with more people in charge of product procurement over the next 90 days to finalize purchase orders.

Likely feeling like he was back in the 1990s when he launched the cigar line, Lambrecht commented, “I am ecstatic to say that again we had people waiting in line to speak about our hemp cigarettes.” Given his past success, Lambrecht being ecstatic is plenty of reason for SING investors to be encouraged about what the new sales channel can mean to revenue, which more than doubled in Q2 from a year earlier to $856,859.

Click here to see the company corporate presentation

SinglePoint will next be meeting with potential buyers and showcasing the Pure American Hemp line at MJBIZCON in Las Vegas on December 11-13.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

 

The post SinglePoint Heating Up with New Cannabis Cigarette Launch appeared first on CannabisFN.

Nabis Holdings Receives Regulatory Approval to Operate its New Assets, Emerald Phoenix and Infusion Edibles in Arizona

VANCOUVER, British Columbia, Oct. 16, 2019 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE:NAB) (OTC: NABIF) (FRA:A2PL) (“NabisTM” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, today announced that it has received all required regulatory approvals to operate the assets of Perpetual Healthcare Inc, Emerald Phoenix, a licensed medical marijuana dispensary located in Phoenix, Arizona and Infusion Edibles, a popular cannabis infused snack and beverage brand. The acquisition of these assets was previously announced on August 12, 2019. Nabis’ portfolio of operating licensing rights has now increased to a total of 11 for retail, cultivation and processing facilities combined in 4 states across the U.S.

“As one of the strongest limited-license, medical cannabis markets in the U.S., Arizona continues to be a priority market for Nabis. Expanding our operations with the Emerald Phoenix dispensary and well-known Infusion Edibles brand better positions us for our next phase of growth. Both businesses have a wide reach in Arizona, including an active registered purchasing patient roster of over 12,000 patients at the dispensary,” said Shay Shnet, CEO & Director of Nabis. “Our team remains focused on continued expansion as well as the development of our innovative product lines and brands.”

Nabis’ Arizona operations now include cultivation, fulfillment, production and retail:

  • The Hub, a 44,000 square foot cultivation, fulfillment and production facility, is located on 2.5 acres of total land and one of the largest industrial warehouses in the Verde Valley. The Hub is also the new home of production for WISP pods in Arizona. This is an exclusive production agreement for the Company.
  • Emerald Phoenix, Nabis’ first operating dispensary licensed to operate in the city of Phoenix (Maricopa County), which serves more than 133,000 unique patients, per the Arizona Department of Health Services August 2019 reporting. This dispensary has an active registered purchasing patient roster of more than 12,000 patients, a healthy marketing outreach and a loyal word of mouth clientele.
  • Infusion Edibles, a highly popular brand of cannabis infused snacks and beverages. Infusion Edibles’ line of products includes baked goods – brownies and cookies; candies – gummies and lollies, and soda – root beer and cherry to name a few flavors. As one of the first medical cannabis kitchens in Arizona, Infusion Edibles produces superior products with outstanding flavors, delivering safe, consistent and effective medication. Under Nabis ownership, the menu will be expanded to include new products and seasonal treats.

Nabis will acquire 100% of the membership units of the Asset for total consideration of USD $15 million (CAD $19.65 million) comprised of USD $7 million in cash, $2 million of Nabis’ common stock, and $6 million deferred for 12 months at 5% interest. The Nabis common stock will be issued in three tranches with each tranche to be priced based on the ten day volume weighted average price calculated on the day prior to issuance. Shares issued are subject to customary regulatory approvals and restrictions.

In connection with the previously announced CFO and VP Investor Relations appointments, the Company announces that 2 million management incentive stock options have been granted, pursuant to the terms of the Company’s stock option plan. The stock options are subject to vesting conditions, are priced at $0.10 per share and expire 5 years after the date of grant.

About Nabis Holdings Inc.
Nabis Holdings is a Canadian investment issuer that invests in high quality cash flowing assets across multiple industries, including real property, securities, cryptocurrency, and all aspects of the U.S. and international cannabis sector. Led by two of the co-founders of MPX Bioceutical, one of the largest takeovers in the U.S. Cannabis space to date, the company has a proven track record in emerging markets to create significant shareholder value. The Company is focused on investing across the entire vertically integrated aspects of the space with a focus on revenue generation, EBITDA and growth.

For more information, please visit https://www.nabisholdings.com/.

Forward-Looking Statements
All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The risks are without limitations: that the acquisitions will be completed by the Company or completed upon the terms disclosed; the price for cannabis and related products will remain consistent and the consumer demand remains strong; availability of financing to the Company to develop the retail locations; retention of key employees and management; changes in State and/or municipal regulations of retail operations and changes in government regulations generally. Important factors that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission and the Alberta Securities Commission.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

For inquiries, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
PH: 212-896-1267
Nabis@kcsa.com

Company Contact:
Shay Shnet, CEO and Director
PH: 905-581-5521 x107
info@nabisholdings.com

Primary Logo

The post Nabis Holdings Receives Regulatory Approval to Operate its New Assets, Emerald Phoenix and Infusion Edibles in Arizona appeared first on CannabisFN.

THC BioMed Licensed to Sell Cannabis Oil

VANCOUVER, Oct, 16, 2019 /CNW/ – THC BioMed Intl Ltd. (“THC BioMed“) (CSE: THC) announces that Health Canada has amended its licence to enable THC BioMed to sell cannabis oil products.

THC BioMed (CNW Group/THC BioMed)

October 17th marks a significant turn for the cannabis industry as we welcome the introduction of edibles. THC BioMed is excited to participate in this momentous occasion with the granting of our oil licence,” commented John Miller, CEO of THC BioMed, “We also will be filing an application to add the sale of extracts, topicals and edibles to our licence in the next few days.”

“We are proud to introduce a brand-new product to the cannabis market, THC Kiss, a proprietary invention of THC BioMed. This is a unique product and it is not something that can be found on the existing gray or legal markets,” said Mr. Miller.

THC Kiss, when approved, will be available through authorized provincial distributers and to THC BioMed’s registered patients.

THC plans to submit an application for product approval for THC Kiss and be subject to the 60-day notice period for new cannabis products becoming available for sale, pursuant to Appendix I of Canada’s updated Cannabis Licence Management Guide.

About THC

THC is an ACMPR Licensed Producer and Canada’s largest supplier of legal Cannabis Genetics. THC is on the leading edge of scientific research and the development of products and services related to the medical cannabis industry. Management believes THC is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC. Forward-looking information is based on certain key expectations and assumptions made by the management of THC. In some cases, you can identify forward-looking statements by the use of words such as “will,” “may,” “would,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “could” and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Although THC believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release and include that (a) THC BioMed will submit an application in the next few days to add the sale of extracts, topicals and edibles to its licence, (b) THC BioMed will introduce THC Kiss to the cannabis market, (c) THC Kiss will be approved by Health Canada or be available as stated, and (d) THC will be on the forefront of this rapidly growing industry. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

SOURCE THC BioMed

President and CEO: John Miller, THC Biomed Intl Ltd., T: 1-844-THCMEDS, E: info@thcbiomed.comCopyright CNW Group 2019

The post THC BioMed Licensed to Sell Cannabis Oil appeared first on CannabisFN.

Westleaf Receives Health Canada Standard Processing Licence

The Company’s large-scale cannabis extraction facility, The Plant, can now begin processing and product formulation in time to meet expected demand of Cannabis 2.0

CALGARY, Oct. 15, 2019 /PRNewswire/ – Westleaf Inc. (the “Company” or “Westleaf“) (TSX-V:WL) (OTCQB:WSLFF) is pleased to announce its large scale cannabis extraction, processing and product formulation facility, The Plant by Westleaf Labs, received a standard processing licence from Health Canada (the “Standard Processing Licence“) and is ready to start operations immediately. The Standard Processing Licence will allow Westleaf to process bulk cannabis to create and sell derivative products through a variety of commercial arrangements.

“This is a major catalyst for Westleaf to generate material revenue through the sale of derivative cannabis products and by offering contract manufacturing services,” said Scott Hurd, President and CEO of Westleaf. “The issuance of the Standard Processing Licence is timely as Westleaf prepares to launch its cannabis 2.0 products upon legalization which is expected on October 17, 2019“.

Cannabis 2.0 is the legalization of the next wave of recreational and medicinal cannabis products currently set to begin in Canada on October 17th, 2019. It will allow cannabis manufacturers and retailers to provide consumers with a wide range of new cannabis products including high quality and safe vape cartridges, edibles, concentrates and other oil products.

The 15,000 square foot Phase I of the facility has been built to European Union good manufacturing practice (GMP) specifications and is designed to process up to approximately 65,000 kgs of dried cannabis per annum into anticipated high quality edibles, concentrates, vape and oil products, including Westleaf’s first in-house product, a line of vape pens under the brand General Admission, as well as products under the Company’s other house brands, Backstage, and wellness brand, Loon. The Plant has an additional 45,000 square feet of space to expand extraction capacity as well as add additional product lines based on consumer preferences once the additional products are licensed post October 17, 2019.

With the pending legalization of cannabis derivative products, Westleaf anticipates strong industry wide demand for efficient extraction, processing and formulation capacity. The scalability of The Plant ensures Westleaf is well positioned to capitalize on the expected demand growth for contract manufacturing, tolling arrangements, white labeling, and in-house product formulation. In July 2019, Westleaf signed its first extraction contract with Delta 9 for white label derivative cannabis products worth at minimum approximately $4 million per annum with an option to increase up to $16 million per annum.

“The Delta 9 contract is the first of what we hope to be a number of similar arrangements between licensed producers, product developers and others who are preparing for the coming legalization of derivative cannabis products such as vapes, edibles, topicals and beverages, or what is called Cannabis 2.0,” noted Hurd. “We are preparing Westleaf to be in a strong position to capitalize on the expected spike in consumer demand for these products later this year and into 2020 and beyond.”

In addition, Westleaf has now satisfied ATB’s condition precedent (receipt of Health Canada standard processing licence) to draw the previously announced $3.7 million of additional capital in the form of a $2.7 million term loan and a $1.0 million line of credit for working capital purposes.

Westleaf Operational Updates:

  • Prairie RecordsNamed the top retailer in Canada by the Grow UP Conference and Expo, Prairie Records is generating revenue through three stores in the Saskatoon region and one in Calgary, with up to 20 more locations under development including downtown Calgary and Edmonton and a flagship store in the tourist centre of Banff, Alberta;

  • Thunderchild Cultivation – Phase I (80,000 square feet) of the large-scale cultivation facility in Battleford, Saskatchewan is fully funded and on track for completion and submission of its Health Canada evidence package for a cannabis standard cultivation licence by the end of 2019.

About Westleaf Inc.

Westleaf is a Canadian cannabis company focused on cannabis brands, extraction and production of derivatives, wholly owned retail, as well as cannabis cultivation. The Company’s Health Canada licensed extraction and processing facility, The Plant, is expected to produce high quality and consistent cannabis derivatives and consumables, both for Westleaf’s in-house brands as well as white label products. Westleaf’s retail concept, Prairie Records, leverages the instinctual tie between recreational cannabis and music with stores operating or in development across Western Canada. The Company’s Thunderchild cultivation facility is scheduled for completion at the end of this year.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release

Cautionary Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, (i) retail cannabis stores that Westleaf plans to open; (ii) the construction of Westleaf’s production facilities and the timing for completion of same; (iii) commencement of production at Westleaf’s production facilities; (iv) commencement of operations at the Plant, its capacity to manufacture and extract cannabis derivative products and corresponding scalability, its ability to provide a competitive advantage by being adaptive to consumer needs and material revenue that may be derived from its operations; (v) products and brands to be produced from Westleaf’s production facilities and the products and services that Westleaf plans to offer; (iv) timing of provincial and federal regulatory approvals; (vii) timing of legalization of certain derivative products and the anticipated benefits and impact on Westleaf; (viii) changes in cannabis consumption habits among Canadians; (ix) anticipated revenue from contractual arrangements with Delta 9; * draw down on credit facilities with ATB; and (xi) the processing and production capabilities of Westleaf’s extracting and cultivation facilities. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: risks relating to the ability to obtain or maintain licenses to retail cannabis products; review of Westleaf’s production facilities by Health Canada and receipt of licenses from Health Canada in respect thereof; future legislative and regulatory developments involving cannabis, including the passing of regulations regarding derivative cannabis products; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the labour market generally and the ability to access, hire and retain employees; the ability of Westleaf’s production facilities to operate and perform at peak production; general business, economic, competitive, political and social uncertainties; the satisfaction of conditions precedent under Westleaf’s credit facilities; timing and completion of construction of Westleaf’s production facilities and retail locations; and the delay or failure to receive board, ATB Financial or regulatory approvals, including any approvals of the TSX Venture Exchange, as applicable. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Westleaf assume no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE Westleaf Inc.

Related Links

http://www.westleaf.com

The post Westleaf Receives Health Canada Standard Processing Licence appeared first on CannabisFN.

Cansortium Inc. Announces Separation of CEO and Chairman Roles; Appoints Neal Hochberg as Chairman. Jose Hidalgo Continues as CEO to Focus Exclusively on Implementing the Company’s Growth Initiatives

MIAMI, Oct. 15, 2019 /CNW/ – Cansortium Inc. (CSE:TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”) today announced that its Board of Directors has elected independent director Neal Hochberg to serve as Non-Executive Chairman. Mr. Hochberg, a Certified Public Accountant, has a distinguished 40 year career in financial services. He was a Financial Advisory partner at both PWC and KPMG and is a Senior Advisor to the leadership of FTI Consulting Forensic & Litigation Consulting segment, previously serving on FTI’s Executive Committee. Recently, he was also appointed by the Supreme Court of Florida to membership on the Florida Board of Bar Examiners.

Cansortium Inc (CNW Group/Cansortium Inc)

Jose Hidalgo will continue as CEO and remain a director of the Company.

Splitting the Chairman and CEO roles will enable Mr. Hidalgo to focus full time on executing the Company’s business plan. Cansortium is undergoing a period of rapid growth with its core, vertically-integrated operations in Florida. Concurrently, the Company is assessing both near and longer term value enhancing initiatives in the Michigan, Texas and Pennsylvania markets.

“This change provides additional bandwidth for Jose and Cansortium’s management to continue their focus on maximizing the value of the Company’s portfolio of assets. During this period of capital markets dislocation and regulatory uncertainty in the cannabis sector, it is critical for our executive team to deploy capital in an efficient manner and execute on key initiatives on time and on budget. The Board is highly engaged in refining the Company’s strategy and supervising management’s execution of that strategy during this important phase of growth for the Company” said Mr. Hochberg.

“I am fully supportive of the Board’s decision to elect Mr. Hochberg as Chairman. I believe that now is the optimal time to separate the Chairman and CEO roles and I am excited to work more closely with Neal as Cansortium’s Chairman,” said Mr. Hidalgo.

For a complete list of Fluent dispensary locations, current promotions and rewards programs and hours of operation, or to explore the entire Fluent product line and place an online order for home delivery anywhere in Florida, visit https://getfluent.com/.

ABOUT CANSORTIUM INC.
Cansortium is a global medical cannabis company operating in highly populous medical cannabis markets with a mission to deliver the highest standards of cannabis care from nursery to lab to shelf. Headquartered in Miami, FL and operating under the recently-launched Fluent™ brand (formerly Knox Medical), the Company through its subsidiaries operates cultivation, processing and dispensary facilities across Florida, Texas, Puerto Rico and a dispensary license in Pennsylvania. The Company also has licensed cultivation facilities in Colombia and Canada with licensing pending in Michigan.

Cansortium Inc.’s common shares and warrants trade on the CSE under the symbol “TIUM.U” and “TIUM.WT.U”, respectively, and on the OTCQB Venture Market under the symbol (OTCQB: CNTMF). Investors can find current financial disclosure and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Forward-Looking Information

Certain information in this news release, may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For information on Cansortium Inc., please visit www.cansortium.com.

SOURCE Cansortium Inc

Jeffrey Reath, Executive Vice-President, Finance and Investor Relations, 786-373-2882 ext. 10007, jeff@cansortium.comCopyright CNW Group 2019

The post Cansortium Inc. Announces Separation of CEO and Chairman Roles; Appoints Neal Hochberg as Chairman. Jose Hidalgo Continues as CEO to Focus Exclusively on Implementing the Company’s Growth Initiatives appeared first on CannabisFN.

YIELD GROWTH Appoints Head of Sales with Extensive Experience Selling Skin Care and Edible Mushroom Wellness Products

Vancouver, British Columbia–(Newsfile Corp. – October 15, 2019) – The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce the appointment of Amber Allen as Head of Sales for Yield Growth’s North American retail distribution.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/48731_b1.jpg

Figure 1: Yield Growth’s new Head of Sales will focus on North American retail distribution.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6377/48731_b2.jpg

Ms. Allen is a seasoned and savvy sales broker bringing decades of experience working with distributors to grow a multitude of brands in the skincare, edible mushrooms and other wellness spaces, including Lavido Skin Care, Love Chock, My Matcha Life, Four Sigmatic, Sun Warrior, Mikei Red Reishi, Thursday Plantation and Kosmea Skin Care. As part of the Yield Growth team, Amber will be tasked with refining the company’s sales strategy to maximize sales in Canada and the USA with new and existing accounts, leveraging her expansive and long standing relationships with skincare and wellness retail distributors cultivated over 15 years in the profession.

“Amber’s qualifications in selling wellness products for both skin care lines and edible mushroom brands make her an ideal candidate to build out our North American retail presence,” says Penny White, CEO of Yield Growth. “Amber’s experience in building out the sales platform for North American brands is particularly interesting as we prepare to launch out wild edible mushroom brand through our subsidiary Flourish Mushroom Labs.”

Amber Allen is the founder of Amber Naturally, a boutique creative firm specializing in sales consulting, social media, content marketing, design, and marketing for natural health and wellness brands. She began her career over fifteen years ago as a personal trainer and nutritionist in Vancouver British Columbia, before parlaying her passion for natural healing into her studies of herbalism and wellness.

The global wellness industry grew 12.8% in the last two years, from a $3.7 trillion market in 2015 to $4.2 trillion in 2017, according to an in-depth research report released by the nonprofit Global Wellness Institute.

The global edible mushrooms market is expected to grow at a CAGR of 7.95% to grow to US$62 billion by 2023, increasing from US$42 billion in 2018, according to a report by Research and Markets. Grand View Research reports that the global healthy snacks market size is expected to reach US$32 billion by 2025.

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and other wellness assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall. Yield Growth is launching a line of edible mushroom wellness products in 2020.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO
Kristina Pillon, Investor Relations
invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages and Flourish Mushroom products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

The post YIELD GROWTH Appoints Head of Sales with Extensive Experience Selling Skin Care and Edible Mushroom Wellness Products appeared first on CannabisFN.

Flurotech Receives Research License From Health Canada

CALGARY, Alberta, Oct. 15, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd.(TSXV: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), a technology company focused on the analytical cannabis and hemp testing market, has been awarded a Research License from Health Canada. The license permits the Company to grow up to 144 cannabis plants from seed or clone and store up to 1 KG at its laboratory and cannabis research facility for use in the development of testing protocols for cannabinoids, heavy metals and other contaminants. Furthermore, the research license will allow for future development projects around pesticide and mold testing applications.

“The research license allows the Company to accelerate the development of new applications of our base platform technology, the CompleTestTM, by not having to rely on third parties as extensively,” states Dr. Trevor MacMillan, Ph.D. and Director of Scientific Research at FluroTech. “Current projects in the development pipeline will be more efficient as the Company has the ability to grow plants in-house with biomarkers or heavy metals to optimize extraction protocols or study the uptake and distribution throughout the plant, receive samples from producers to expand our reference database, and establish decarboxylation procedures to test for cannabinoids throughout the entire supply chain. This will provide valuable data to producers working on products for the next wave of legalization.”

The Company expects to release a low THCA testing protocol for hemp in the next month and release a cadmium testing protocol, the first of four heavy metal protocols, soon thereafter. Each new protocol represents a new revenue stream for the Company and increased product differentiation from competitors utilizing HPLC technology.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the benefits to be realized from the Research License, the release of a low THCA testing protocol for hemp and the timing thereof, the release of a cadmium testing protocol and the timing thereof and the benefits of such additional product lines.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTestTM and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, the market for a low THCA testing protocol for hemp and the market for cadmium testing, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology, failure to reach commercialization of the technology, failure to realize the anticipated benefits from the Research License, a lack of demand for low THCA and cadmium testing protocols, and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Primary Logo

The post Flurotech Receives Research License From Health Canada appeared first on CannabisFN.

Next Green Wave Completes Third Premium Cannabis Harvest

Vancouver, British Columbia–(Newsfile Corp. – October 11, 2019) – Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX: NXGWF) (“Next Green Wave”, “NGW” or the “Company”) is pleased to announce that it is processing its third cannabis harvest that will be sold for consumption as premium whole flower product, through its partner brands at selected dispensaries throughout California. The cannabis grown by NGW has consistently passed strict category three testing (CAT3) and meets all premium standards for the California market.

Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/cda1adc08afead421de8c2529f5fc50b

SDC cannabis products now available at Columbia Care

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_nextgreenwave.jpg

Next Green Wave is continuing to build out its distribution strategy to deliver value to top tier dispensaries through its growing brands and products. Similar to a pharmaceutical distribution model, this will allow the company to bypass third party distributors, improve operational efficiency and deliver direct to the retailer. We are proud to announce that Columbia Care dispensaries have now been added to our growing network.

“In less than 6 months since opening our flagship facility, we have completed three harvests of premium quality, high THC cannabis, as well as fully scaled the entire space. As such, the facility is now in a perpetual harvest cycle in which roughly 14% of the flowering space is being processed every 10-14 days. At the same time, we are fortunate to have recently sourced and hired key additional talent to support and facilitate our expanding operations. We are now cultivating at full capacity and our employees will continue to play a significant role as we expand our market share by supplying the highest quality cannabis products to market in a timely fashion,” stated CEO Mike Jennings.

Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/2673a3906f96494a7eb3602354bfa1ca

One of fourteen 1,300 sq ft growing rooms, two rooms will be harvested every 10-14 days

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_f5e3f5d274b57885_003full.jpg

NGW is a fully integrated premium cannabis producer with 8 legacy brands and over 45 products marketed through its WEARESDC brand house. Based in Coalinga, California the company owns and operates a 35,000 sq ft state-of-the-art cultivation facility and is currently expanding extraction and other operations on its cannabis zoned campus. NGW has a seed library of over 120 cannabis strains which include multiple award-winning genetics and cultivars and is developing its nursery cloning operations with bio-tech leader Intrexon. To find out more visit us at www.nextgreenwave.com or follow us on Twitter, Instagram, or LinkedIn.

On behalf of the board,

Michael Jennings, CEO
Next Green Wave Holdings Inc.

For more information regarding Next Green Wave, contact:
Caroline Klukowski
VP Corp. Development
Tel: +1 (778) 589-2848
IR@nextgreenwave.com

Next Green Wave Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the preliminary prospectus, including without limitation dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; NGW’s limited operating history and lack of historical profits; reliance on management; NGW’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of Tranche 1 and Tranche 2 of the Notes; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled “Risk Factors” in NGW’s prospectus. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although NGW has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. NGW no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

Corporate Logo

The post Next Green Wave Completes Third Premium Cannabis Harvest appeared first on CannabisFN.

cbdMD Launches Save Mart Partnership with Appearance by Quinton “Rampage” Jackson

CHARLOTTE, N.C., Oct. 11, 2019 /PRNewswire/ — cbdMD, Inc. (NYSE American: YCBD), a nationally recognized consumer cannabidiol (CBD) brand, is proud to announce its partnership with Save Mart in Modesto, CA, a retailer which operates 207 traditional and price impact stores under the banners of Save Mart, Lucky, Lucky California, FoodMaxx, S-Mart Foods, and Maxx Value Foods. The launch of this partnership will be celebrated on Saturday, October 12 with an appearance by Team cbdMD athlete, former UFC Champion and current Bellator MMA fighter, Quinton “Rampage” Jackson.

Team cbdMD athlete and former UFC Champion Quinton "Rampage" Jackson

The cbdMD partnership with the Save Mart location in Modesto, CA allows this location to be the first Save Mart to provide CBD offerings to their customers. With 26 different cbdMD products available for purchase, consumers can choose from a wide array of tinctures, topicals, capsules, bath bombs and Paw cbd pet products.

“Save Mart has been providing their customers with premium products since 1952,” said Pancho Mangual, EVP, Sales and Expansion for cbdMD. “At cbdMD, we are honored to partner with them to continue their legacy.”

cbdMD encourages patrons to attend the product demonstration from 1pm-5pm at the Save Mart located at 3401 Oakdale Road, Modesto, CA 95357. Quinton “Rampage” Jackson will be available for a fan meet and greet from 2pm to 4pm. Jackson has been a longtime advocate for cbdMD and accredits his usage of cbdMD products for extending his competitive career in combat sports.

About The Save Mart Companies
Based in the heart of the Central Valley, The Save Mart Companies is committed to sourcing a wide variety of local products to ensure that ‘fresh comes first’ for neighborhoods throughout Northern/Central California and Northern Nevada. The company has annual sales of over $4 billion, employs nearly 16,000 team members and operates 207 traditional and price impact stores under the banners of Save Mart, Lucky, Lucky California, FoodMaxx, S-Mart Foods, and Maxx Value Foods. In addition to its retail operation, The Save Mart Companies owns and operates distribution centers in Roseville and Turlock. The company also operates Smart Refrigerated Transport and is a voting partner in Super Store Industries (SSI), which owns and operates a distribution center in Lathrop, Mid Valley Dairy in Fairfield, and Sunnyside Farms ice cream plant in Turlock.

About cbdMD
cbdMD, Inc. is a nationally recognized consumer cannabidiol (CBD) brand whose current products include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, and CBD pet products. cbdMD is also the proud partner with the BIG3 Basketball League, Barstool Sports, Bellator MMA, Life Time, Inc. and Nitro Circus. cbdMD has one of the largest rosters of professional sports athletes who are part of “Team cbdMD.” To learn more about cbdMD and our comprehensive line of over 100 SKUs of U.S. produced, THC-free CBD products, please visit: www.cbdmd.com or follow cbdMD on Instagram and Facebook or visit one of our 3,000 retail outlets that carry cbdMD products.

Forward-Looking Statements
This press release contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ”should,” ”may,” ”intends,” ”anticipates,” ”believes,” ”estimates,” ”projects,” ”forecasts,” ”expects,” ”plans,” and ”proposes.” These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, including, but not limited our ability to, our ability to expand our sales of our CBD products through our partnership with The Save Mart Companies, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” in cbdMD, Inc.’s Annual Report on Form 10-K for the fiscal year ended September 30, 2018, as filed with the Securities and Exchange Commission (the “SEC”) on December 12, 2018, our Quarterly Report on Form 10-Q for the period ended March 31, 2019, as filed with the SEC on May 15, 2019, our Quarterly Report on Form 10-Q for the period ended June 30, 2019 as filed with the SEC on August 14, 2019 and our other filings with the SEC. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are generally outside the control of cbdMD, Inc. and are difficult to predict. cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law. The information which appears on our websites and our social media platforms, including, but not limited to, Instagram and Facebook, is not part of this press release. The information which appears on Save Mart’s website and its social media platforms is not part of this press release.

CONTACT: Investor Contact: John Weston, 704-249-9515, john.weston@cbdmd.com, Additional Contact: pr@cbdmd.com.

(PRNewsfoto/cbdMD)

The post cbdMD Launches Save Mart Partnership with Appearance by Quinton “Rampage” Jackson appeared first on CannabisFN.

Harvest On Schedule, Product Entering Additional Dispensaries

Vancouver, British Columbia–(Newsfile Corp. – October 11, 2019) – Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX: NXGWF) (“Next Green Wave”, “NGW” or the “Company”) is pleased to announce that it is processing its third cannabis harvest that will be sold for consumption as premium whole flower product, through its partner brands at selected dispensaries throughout California. The cannabis grown by NGW has consistently passed strict category three testing (CAT3) and meets all premium standards for the California market.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6127/48696_2nextgreenwave.jpg

SDC cannabis products now available at Columbia Care

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_nextgreenwave.jpg

Next Green Wave is continuing to build out its distribution strategy to deliver value to top tier dispensaries through its growing brands and products. Similar to a pharmaceutical distribution model, this will allow the company to bypass third party distributors, improve operational efficiency and deliver direct to the retailer. We are proud to announce that Columbia Care dispensaries have now been added to our growing network.

“In less than 6 months since opening our flagship facility, we have completed three harvests of premium quality, high THC cannabis, as well as fully scaled the entire space. As such, the facility is now in a perpetual harvest cycle in which roughly 14% of the flowering space is being processed every 10-14 days. At the same time, we are fortunate to have recently sourced and hired key additional talent to support and facilitate our expanding operations. We are now cultivating at full capacity and our employees will continue to play a significant role as we expand our market share by supplying the highest quality cannabis products to market in a timely fashion,” stated CEO Mike Jennings.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6127/48696_f5e3f5d274b57885_003.jpg

One of fourteen 1,300 sq ft growing rooms, two rooms will be harvested every 10-14 days

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6127/48696_f5e3f5d274b57885_003full.jpg

NGW is a fully integrated premium cannabis producer with 8 legacy brands and over 45 products marketed through its WEARESDC brand house. Based in Coalinga, California the company owns and operates a 35,000 sq ft state-of-the-art cultivation facility and is currently expanding extraction and other operations on its cannabis zoned campus. NGW has a seed library of over 120 cannabis strains which include multiple award-winning genetics and cultivars and is developing its nursery cloning operations with bio-tech leader Intrexon. To find out more visit us at www.nextgreenwave.com or follow us on TwitterInstagram, or LinkedIn.

On behalf of the board,

Michael Jennings, CEO
Next Green Wave Holdings Inc.

For more information regarding Next Green Wave, contact:
Caroline Klukowski
VP Corp. Development
Tel: +1 (778) 589-2848
IR@nextgreenwave.com

Next Green Wave Forward Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Such risks and uncertainties include, among others, the risk factors included in the preliminary prospectus, including without limitation dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete construction of its proposed facilities in a timely manner; engaging in activities which currently are illegal under US federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; NGW’s limited operating history and lack of historical profits; reliance on management; NGW’s requirements for additional financing, and the effect of capital market conditions and other factors on capital availability, including closing of Tranche 1 and Tranche 2 of the Notes; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. Readers are encouraged to the review the section titled “Risk Factors” in NGW’s prospectus. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although NGW has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. NGW no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48696

Source: Newsfile Corp. (October 11, 2019 – 8:34 AM EDT)

News by QuoteMedia

The post Harvest On Schedule, Product Entering Additional Dispensaries appeared first on CannabisFN.

Harborside Inc. Acquires Full Ownership of San Leandro Wellness Solutions

OAKLAND, CA and TORONTO, Oct. 11, 2019 /CNW/ – Harborside Inc. (“Harborside” or the “Company”) (CSE: HBOR), a California-focused, vertically integrated cannabis enterprise, announced today it has acquired full ownership of San Leandro Wellness Solutions, Inc. (the “Transaction”). Harborside previously owned 50% of the dispensary under a joint venture with Dark Heart Nursery, and would have provided management services to the store upon opening in Q4 of this year. With the close of this Transaction, Harborside now operates three dispensaries in the San Francisco Bay Area, alongside their flagship Oakland and San Jose locations. Construction on the ~7,000 square foot retail facility commenced in 2017 and is expected to open later this year as a Harborside branded store. The facility is permitted for retail, distribution and manufacturing.

Harborside (CNW Group/Harborside Inc.)

The San Leandro dispensary is strategically located along the busy Interstate 880 corridor between Oakland and San Jose, one of the most heavily trafficked stretches of highway in Northern California. The store will carry both medical and adult-use products, including Harborside’s own KEY line of cannabis products, and will also offer delivery services. This new retail location will be one of just three licensed dispensaries in the city of San Leandro.

“Harborside accelerated this retail expansion into San Leandro after going public in June 2019, and we are delighted to provide another Northern California community with our quality products,” said Andrew Berman, CEO of Harborside. “Our goal from the very beginning was to establish ourselves as a pre-eminent cannabis retailer in Northern California. This additional retail opportunity will allow us to further engage with consumers and secure our reputation as a trusted resource for all cannabis needs. We are delighted to be in San Leandro and be part of its thriving community.”

“Harborside has been serving the Bay Area for thirteen years and we are thrilled to announce today that we will be bringing our gold-standard business model and award-winning services and products to San Leandro,” said Steve DeAngelo, co-founder and Chairman Emeritus of Harborside. “We started as one of the first six medical cannabis dispensaries licensed in the United States. Since then, we have grown into a leading cultivator, introduced our own consumer brands to the market, expanded our retail footprint, and played a leading role in ending prohibition on access to cannabis. Our goal is the same as it has always been: to provide our clients with safe, tested, high-quality cannabis products at affordable prices with excellent customer service.”

About Harborside:
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating two of the major dispensaries in the San Francisco Bay Area, two dispensaries in Oregon and a cultivation facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States. Harborside is currently a publicly listed company on the Canadian Securities Exchange (“CSE”) trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com, including in Harborside’s Listing Statement dated May 30, 2019.

Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking-statements relate to, among other things, future plans relating to the San Leandro dispensary.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the California cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in the State of California; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

For the latest news, activities, and media coverage, please visit the Harborside corporate website at www.investharborside.com or connect with us on LinkedIn, Facebook, and Twitter.

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Harborside Inc.

For further information: Company Contact: Harborside Inc., Andrew Berman, CEO, (510) 610-7444; Media Contact: MATTIO Communications, Mel Trecha, mel@mattio.com; Investor Contact: MATTIO, Communications, Matt Chesler, CFA, hbor@mattio.com

The post Harborside Inc. Acquires Full Ownership of San Leandro Wellness Solutions appeared first on CannabisFN.

New West Summit Brings Together Cannabis Innovators in San Francisco

The New West Summit is taking place at NWS5 in San Francisco, CA on October 10 and 11, bringing together cannabis, technology, science, media and investment firms. With over 50 exhibitors and two days of high-impact presentations, investors, companies and advocates can network with some of the industry’s preeminent thought leaders and innovators.

Featured speakers at the event include:

  • Actress, author and activist Alicia Silverstone
  • Rapper, actor and entrepreneur Killer Mike
  • Platinum-selling artist and filmmaker Michael Franti
  • Former CEO of Men’s Wearhouse George Zimmer
  • CNBC personality Timothy Seymour
  • Activist and Harborside Co-Founder Steve DeAngelo
  • Advocate and Filmmaker Mara Gordon
  • Cannabis researcher Dr. Sue Sisley

Steve DeAngelo Co-Founder and Chairman Emeritus of Harborside, a vertically integrated California cannabis company. Steve is also known as “The Father of the Cannabis Industry”.

CFN Media will provide full coverage of the conference via exclusive interviews with thought leaders and pioneering companies. If you’re company is interested in an interview, please contact Frank Lane at flane@cannabisfn.com or (800) 517-5820 to schedule a time. The coverage will be published on CannabisFN’s Video Library over the coming weeks.

Individuals or companies interested in attending the conference can buy tickets online at:

https://newwestsummit.com/get-tickets/

See other upcoming conferences on CannabisFN.com’s conference calendar:

https://www.cannabisfn.com/event-calendar/

About New West Summit

New West Summit focuses exclusively on technological advancements in the cannabis space and the disruptive forces at play in science, investment and media for this evolving industry. The October 10-11 event at Bespoke Event Center in San Francisco, California, will feature highly vetted & curated activations and participants with 60+ exhibitors, 40+ panels, 100+ speakers, an investment round tables, showcase retail pop-up’s, VIP afterparties and more. Learn more at www.NewWestSummit.com

About CFN Media

For Visitors and Viewers 

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies 

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

The post New West Summit Brings Together Cannabis Innovators in San Francisco appeared first on CannabisFN.

YIELD GROWTH Completes Acquisition of Catalogue of Edible Mushroom Formulas and Launches Flourish Mushroom Labs

VANCOUVER, British Columbia, Oct. 10, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that its wholly owned subsidiary Flourish Mushroom Labs Inc. has completed the acquisition, announced on September 24, 2019, of a catalogue of mushroom formulas as the foundation of a mushroom edibles business.

The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer’s choice. The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.

The global edible mushrooms market is expected to grow at a CAGR of 7.95% to grow to US$62 billion by 2023, increasing from US$42 billion in 2018, according to a report by Research and Markets. Grand View Research reports that the global healthy snacks market size is expected to reach US$32 billion by 2025.

According to healthline.com, studies have shown that cordyceps (medicinal mushrooms) boost exercise performance, improve memory and sex drive, slow growth of tumors and can improve heart health. A study published in The Journal of Alzheimer’s Disease, as reported by the BBC, found that a unique antioxidant present in mushrooms could have a protective effect on the brain, and the more mushrooms people ate, the better they performed on tests of thinking and processing.

“Learning and memory are the core cognitive functions of the human brain,” says Penny White, Yield CEO. “With a rapid decline of age affecting the population, cognitive deficit is leading to many neurological diseases. Flourish recognizes the early prevention needed for declining learning and memory to conduct research into creating edible products combining the mushroom medicine for a broad potential market.”

Included in the acquisition is know-how and research related to edible mushrooms that could be used in the formulations and various health benefits that can accrue to people eating those mushrooms, as determined by researching data published from clinical trials and from knowledge of Chinese, Tibetan and Ayurvedic medicine. The varieties of mushrooms to be used in the formulations include Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas, Cordyceps and other wild varietals. The research and data on health benefits are included in the acquisition by Flourish.

Flourish purchased the formulations and all know-how and data related to the formulations with the issuance of 120,000 common shares of Yield Growth at a deemed value of $0.25 per share.

According to The New York Times, on September 4, 2019 Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research, to study compounds like LSD and psilocybin for a range of mental health problems, including anorexia, addiction and depression. The center is the first of its kind in the country, established with $17 million in commitments from wealthy private donors and a foundation. CNBC says that investors are starting to bet big on psychedelic medicine with ATAI Life Sciences completing a $40 million round in March 2019 at a $240,000,000 valuation.

By mutual agreement Yield Growth is not proceeding with any investment into Absolem Health Corp.

About The Yield Growth Corp.

The Yield Growth Corp. is building and operating hemp, cannabis and other wellness assets in what the Global Wellness Institute reports is a $4.2 trillion-dollar global wellness market. The Yield Growth management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy and Aritzia. Its all-natural hemp skin care brand, Urban Juve, has signed distribution agreements in Canada, Columbia, Brazil, Greece and Cypress and through its distributor network has access to over 8,000 retail locations. Urban Juve has been featured in UK Vogue, Vanity Fair UK and Elle Canada and has an alliance with leading online beauty community, ipsy. Yield Growth’s Wright & Well brands are launching a THC/CBD line of topical products in Oregon and a CBD from hemp topicals line in California this fall.

Through its subsidiaries, Yield Growth has over 200 proprietary beauty, wellness, edibles and beverage formulas for commercialization. It had filed 12 patents to protect its extraction method and formulas. Yield Growth is in revenue through multiple streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well and UJ Beverages products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/287af419-ba73-4828-901e-ce2b4b26e5f6

Primary Logo

The Yield Growth Corp – Flourish Mushroom Labs Inc
Varieties of mushrooms to be used in the edible formulations include Lion’s Mane, Turkey Tail, Reishi, Shitake, Chagas, and Cordyceps, among other wild varietals

 

Source: GlobeNewswire (October 10, 2019 – 7:40 AM EDT)

News by QuoteMedia

The post YIELD GROWTH Completes Acquisition of Catalogue of Edible Mushroom Formulas and Launches Flourish Mushroom Labs appeared first on CannabisFN.

MediPharm Labs Closes New $38.7 Million Upsized Credit Facility with a Top 5 Canadian Schedule 1 Bank to Support Growth

TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation, purification and cannabinoid isolation, is pleased to announce its wholly-owned subsidiary, MediPharm Labs Inc. (“MediPharm”) has closed a credit agreement (the “Credit Facility”) with a top 5 Canadian Schedule 1 bank (the “Bank”) for an aggregate $38.7 million. The Credit Facility was upsized from the previously announced committed term sheet of $20.0 million, and is comprised of a revolving term facility, a non-revolving term facility and a non-revolving delayed draw term facility.

“With the successful upsizing of our Credit Facility and the proceeds from our recent $75 million bought deal equity offering, we have strengthened our balance sheet and our ability to execute our global business plan to efficiently seize the growth opportunities before us,” said Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “In particular, this enlarged facility will enhance liquidity and support the delivery of our stated Canadian and Australian capex strategy, to ramp up of production capacity to meet contracted and expected demand for our new product classes.”

The Company’s $38.7 million Credit Facility was upsized from the previously announced committed term sheet of $20.0 million. The revolving term facility is for up to $25.0 million subject to the Company’s borrowing base, can be drawn in Canadian or Australian dollars, has a 1-year term and is to be used for Canadian and Australian working capital. The $5.7 million non-revolving term facility was fully drawn on closing, has a 3-year term and was used to refinance and reduce the interest expense of an existing mortgage. The non-revolving delayed draw term facility of up to $8.0 million has a 3-year term and is to be used to fund capital expenditures.

“MediPharm Labs has distinguished itself in the cannabis industry as a diverse, profitable, risk-managed growth company,” said Mr. McCutcheon. “The closing of the Credit Facility required extensive due diligence of our current production site and capabilities, along with a detailed review of our Company’s expected revenue growth, liquidity and regulatory compliance. The Credit Facility will add to our strong balance sheet to assist us in executing on our business strategy and accelerating our domestic and international expansion strategies.”

The Credit Facility will bear interest at the Bank’s prime lending rate plus a certain per cent per annum dependent upon the Company’s debt to EBITDA ratio. The Credit Facility has a first ranking general security interest in the Company’s assets and can be repaid without penalty.

About MediPharm Labs Corp.

Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-grade cannabis oil and concentrates and advanced derivative products utilizing cGMP (current Good Manufacturing Practices) designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with 5 primary extraction lines having 300,000 KG of annual processing capacity to deliver pure, safe and precisely-dosed cannabis products for its customers. Through the Company’s wholesale, private and white label platform, MediPharm Labs formulates, processes, packages and distributes active pharmaceutical ingredients and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 KG of annual processing capacity.

For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, capital expenditures for the Barrie and Australian facilities, ramp up of production capacity, expected demand for new product classes, execution of our business strategy, accelerating our domestic and international expansion strategies, the completion of the Australian facility and the processing capacity of the Australian facility. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

 

Primary Logo

 

Source: GlobeNewswire (October 10, 2019 – 7:31 AM EDT)

News by QuoteMedia

The post MediPharm Labs Closes New $38.7 Million Upsized Credit Facility with a Top 5 Canadian Schedule 1 Bank to Support Growth appeared first on CannabisFN.

SINGLEPOINT LAUNCHES PURE AMERICAN HEMP™ CIGARETTES; CATCHING FIRE AT NACS

SinglePoint takes multiple orders and collects sales leads for over 2500 interest retail stores.

Orders yours NOW by calling 855-203-3318 or visit www.pure-hemp.com

Phoenix, AZ October 9, 2019 – SinglePoint Inc. (OTCQB:SING) is pleased to announce major success at the 2019 National Association of Convenience Stores show (NACS) in Atlanta. As the master distributor of Pure American Hemp Cigarettes™, SinglePoint sold multiple cases during the show to retail store owners representing approximately 2500 stores. SinglePoint was able to directly interact with interested store owners, national distributors, and buying groups, accounting for well over 20,000 retail locations. This week the company has ordered additional product to meet demand.

With the passage of the 2018 Farm Bill and the mainstreaming of CBD hemp flower, the market for innovative products such as hemp cigarettes is growing rapidly. There is a significant need for reliable suppliers with the capacity to move product. Its demonstrated capacity to deliver has established SinglePoint as one of the dominant players in the CBD and hemp marketplace.

“Our success at NACS was beyond what anybody in our group imagined. It truly gave us deep insight to how large of an opportunity this is. With interest from parties representing over 20,000 retail locations we are excited to move into this   convenience store industry accounting for over 150,000 locations. Over the next 90 days we will be following up with these owners to finalize their purchase orders. I am ecstatic to say that again we had people waiting in line to speak about our hemp cigarettes. It reminded me of the successful product introduction of Premium Cigars International and PrimeTime™ to the convenience store industry. We expect this new product to dramatically increase revenue in the near future.” Greg Lambrecht CEO SinglePoint.

BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will surpass $20 billion by 2024 while New York-based investment bank Cowen & Co, estimates that the market could pull in $15 billion by 2025. The smokable hemp market currently represents approximately 2% of the overall CBD market, but with a 250% growth from 2017 to 2018, Brightfield Group, a Chicago-based cannabis market research firm, identifies dried and smokable hemp flowers as one of the fastest-growing segments of the CBD market.

Due to the success at NACS the company’s next major retail show event will be December 11-13 at the MJBIZCON in Las Vegas. The company will be introducing its innovative hemp cigarette, pioneering a new industry product for dispensaries.

About SinglePoint, Inc.

SinglePoint, Inc (SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base. Through SingleSeed, the company is providing products and services to the cannabis industry.

Connect on social media at:
https://www.facebook.com/SinglePointMobile
https://twitter.com/_SinglePoint
https://www.linkedin.com/company/singlepoint
For more information visit: www.SinglePoint.com 

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Corporate Communication

SinglePoint Inc.

855-711-2009

investors@SinglePoint.com

SinglePoint.com

 

The post SINGLEPOINT LAUNCHES PURE AMERICAN HEMP™ CIGARETTES; CATCHING FIRE AT NACS appeared first on CannabisFN.

FluroTech to Present at Upcoming MjMicro Conference in Beverley Hills

CALGARY, Alberta, Oct. 09, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF), (“FluroTech” or the “Company”), an aspiring leader in analytical cannabis and hemp testing technologies, is pleased to be one of the featured presenters at the upcoming MjMicro conference in Beverley Hills, California. The conference, which will be held on October 16 at the Sofitel Hotel, is an invitational forum that unites publicly traded and emerging growth private cannabis companies led by seasoned executives with high net-worth investors and financial analysts.

FluroTech CEO, Danny Dalla Longa, will host a featured presentation to update investors and analysts on recent company milestones. “Rex Kary, FluroTech’s COO, will accompany me to MjMicro and we’re both looking forward to meeting individual and institutional investors with a focus on discussing investments and future growth plans including potential joint ventures,” stated Danny Dalla Longa. “Recent developments in our hemp testing capabilities along with an update on our biotracking technology should prove to be of great interest to attendees.”

The Company will be performing live onsite demos of the CompleTest™, demonstrating its accuracy, speed, ease-of-use, portability, and reliability at an affordable price.

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
7 – 3535 Research Road NW
Calgary, AB T2L 2K8
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the commercialization of the Company’s biotracker technology and timing thereof, the potential uses of the biotracker technology and the benefits thereof and the anticipated performance of the Company’s biotracker and CompleTest™ technologies.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTest™ and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology, failure to reach commercialization of the technology and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Primary Logo

The post FluroTech to Present at Upcoming MjMicro Conference in Beverley Hills appeared first on CannabisFN.

Cannabis Consumer Price Index: Executive Summary – August 2019 (Released October 2019)

The one-of-a-kind Cannabis Market CPI is a benchmark of retail sales pricing across cannabis products in select legalized U.S. markets. The index currently reports sales in Arizona, California, Colorado, Nevada, and Oregon, states that generated more than 60 percent of legalized U.S. sales in 2018. Underlying pricing data is the compilation of actual dispensary transactions captured by BDS Analytics’ GreenEdge™ Retail Sales Tracking Platform.

The baseline of measurement represents the launch of adult-use sales in California in January of 2018. In order to standardize retail pricing data for Flower and Concentrates, all transactions are normalized to price per gram.

For Ingestible, Topicals and Vapes, sales are converted to a price per unit measure. BDS Analytics’ CPI is unique in its ability to index retail pricing across all product categories, a significant insight considering the rapid market growth largely driven by branded products in all categories.

BDS Analytics’ CPI for August 2019 stands at 104.01, representing less than two-tenths of a percent decrease from the trailing month. Compared to August 2018, the CPI average retail prices have declined nearly three percent. Year-to-date average retail prices have declined less than one percent.

The index score is positive for Pre-Rolled joints, Ingestible and Topicals, indicating an increase of the average retail price of these product categories relative to January 2018. Other product categories, such as Flower, Vape, and Dabbable Concentrates (referenced in table as ‘Concentrates – No Vape’), have negative CPI scores. The average retail prices of Flower, Dabbable Concentrates, and Vape all increased by one point, when compared to the trailing month.

GreenEdge® Insights: In August 2019, legal cannabis sales at dispensaries across Arizona, California, Colorado, Oregon, and Nevada reached a combined $639.2 million, a four percent increase from the trailing month and a 21 percent increase from the prior August. After years of declining flower prices, a temporary floor appears to have been reached in the fourth-quarter of 2018. Thus far in 2019 we have seen a rebound as flower prices have steadily increased over the past few months. The phenomenon of higher flower prices isn’t geographically isolated as the trend is evident in multiple markets.

With significant flower production having been allocated for to extraction to feed Concentrates, Vape and other product categories, the supply of flower for smoking has diminished over time.

Recent negative news for the vape category could have a chilling effect and could further boost demand for flower in the near term. With limited supply, should demand for flower continue to strengthen we can anticipate further increases in flower pricing.

Stay tuned for the next installment of the CPI for a recap of Cannabis sales trends with September data.

For further details about these insights and more, please contact info@bdsanalytics.com.

About BDS Analytics:

Headquartered in Boulder, Colorado, BDS Analytics provides businesses with comprehensive, actionable, and accurate cannabinoid market intelligence and consumer research. The company provides a holistic understanding of the cannabinoid market by producing insights from tracking and categorizing millions of individual consumer transactions, extensive and detailed consumer research and generating market-wide cannabinoid industry financial projections, all delivered through its market-leading GreenEdge® platform. To learn more about how you can utilize BDS Analytics’ industry-leading market research, please visit www.bdsanalytics.com.

BDS Analytics’ have an exclusive media partnership with CFN Media, the leading financial network in Cannabis.

The post Cannabis Consumer Price Index: Executive Summary – August 2019 (Released October 2019) appeared first on CannabisFN.

YIELD GROWTH Announces Urban Juve Skin Awakening Anti-aging Serum with Hemp Oil Featured in Vanity Fair UK

VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE — The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) is pleased to announce that the Urban Juve Skin Awakening Anti-aging Serum is featured in the November issue of Vanity Fair UK, which is now available on newsstands. The latest product feature follows other high-quality beauty and lifestyle publications that included Urban Juve products, such as British Vogue and Elle Canada.

Vanity Fair UK has sophisticated and highly affluent readers. The feature in Vanity Fair UK includes Urban Juve in its beauty showcase called “The Vanity Box,” showcasing a range of handpicked luxury beauty products all perfectly suited to its affluent readers. The November issue of Vanity Fair UK, which is a special edition on art featuring superstar Joaquin Phoenix on the cover, is now available on newsstands.

Yield Growth is well poised to participate in what Jefferies LLC estimates in an April 23, 2019 research report, could be a $25 billion CBD beauty industry in 10 years. It has been rapidly expanding distribution of its Urban Juve hemp powered luxury skin care line through Canada, the U.S., South America and Europe and is expected to launch its full line of products in Europe within a few months. It is launching a full line of CBD and THC topical products under the Wright & Well brand in the U.S. this month.

According to Adroit Market Research, “Large scale retailers have stepped in to support the CBD industry, post the introduction of the 2018 Farm Bill. Since January 2019, Neiman Marcus initiated introducing a wide range of CBD infused products in its stores, sourced from the leading brands. Recently, Sephora announced the introduction of a CBD section in their stores. Key beverages company Coca Cola announced its interest in CBD beverages. Target also invested in a limited-time offer of CBD oil.”

The Skin Awakening Anti-aging Serum is one of Urban Juve’s most popular products. Inspired by Ayurveda, an ancient mind-body-spirit healing system, the serum deeply nourishes and rejuvenates skin. Like all Urban Juve products, it’s made with clean, natural ingredients.

“Sea buckthorn oil is rich in minerals, antioxidants, fatty acids and plant sterols that help to nourish the skin,” says Bhavna Solecki, Director of Product Development for Urban Juve. “Hemp root oil, which we derive from the cannabis plant helps boost transdermal absorption. This serum helps smooth fine lines and prevents signs of aging and the plant-derived hyaluronic acid makes skin appear more plump and hydrated.”

About The Yield Growth Corp.

The Yield Growth Corp. develops, manufactures and distributes cannabis and hemp infused luxury product brands Urban Juve and Wright & Well and has a catalogue of over 200 wellness and beauty formulas. It intends to disrupt the international wellness market, which is a $4.2 trillion global economy, according to the Global Wellness Institute, by connecting ancient healing with modern science and technology. Its management team has deep experience with global brands including Johnson & Johnson, Procter & Gamble, M·A·C Cosmetics, Skechers, Best Buy, Aritzia, Coca-Cola and Pepsi Corporation. Yield Growth serves mainstream luxury consumers who seek sophisticated wellness products. Its flagship consumer brand, Urban Juve, has proprietary, patent-pending hemp root extraction technology and has 12 patents pending. Yield Growth is building sophisticated international distribution channels and has multiple revenue streams including licensing, services and product sales.

For more information about Yield Growth, visit www.yieldgrowth.com or follow @yieldgrowth on Instagram. Visit www.urbanjuve.com and #findyourjuve across social platforms to learn, engage and shop.

Investor Relations Contacts:

Penny White, President & CEO

Kristina Pillon, Investor Relations

invest@yieldgrowth.com

1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, intellectual property protection, and sale of, and demand for, Urban Juve, Wright & Well, UJ Beverages and UJ Edibles products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Yield Growth cautions readers not to place undue reliance on forward-looking statements provided by Yield Growth, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Yield Growth expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Source: The Yield Growth Corp.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/53e0f41b-2ed8-49bf-867f-cdf29b9bfe00

Primary Logo

The post YIELD GROWTH Announces Urban Juve Skin Awakening Anti-aging Serum with Hemp Oil Featured in Vanity Fair UK appeared first on CannabisFN.

Priming for Expansion, GreenStar Strikes a Deal with Progressive Herbs

GreenStar Biosciences Corp. (CSE: GSTR) already had a strong cannabis market presence through its stake in Cowlitz County Cannabis Cultivation, a leading player in Washington State. Primed for expansion, GreenStar has struck a deal with Progressive Herbs Inc., forging a new joint venture that should make all involved even stronger.

Cowlitz County Cannabis is a Tier 2 producer in Washington widely known for sourcing premium cannabis at fair prices and three popular brands: Hi Guys, Dab Dudes and Cowlitz Gold

Cowlitz’s Product Lines

The new JV between GreenStar and Progressive, called Capri PHGS LLC, was kicked off with a pilot cultivation evaluation of a new, proprietary growing system owned by Progressive and its affiliate Aggressively Organic, Inc.

The initial study of the growing system showed the technology can produce cannabis plants that have much higher levels of cannabinoids than similar strains on the market today, along with several other important benefits for cannabis operators.

Capri JV Partnership

Vancouver-based GreenStar and Indiana-based Progressive are 50/50 owners in Capri. Per the deal, the JV has exclusive rights to utilize the proprietary cultivation technology for a sustainable, inexpensive growing system known as Micro Dendritic Pods™. The strategy is for Capri to develop, manufacture, commercialize and sell products grown with the Micro Dendritic Pods technology for sales globally in the cannabis, hemp, medical and biopharmaceuticals markets.

The Micro Dendritic Pod Technology in Action

Click Here to Stay up to date with GreenStar Biosciences 

The two companies and their affiliates have an opportunity to leverage their individual successes. 

Cowlitz’s products, including pre-rolls, flower (cannabis buds), BHO (butane hash oil) waxes, vaporizer cartridges and crystallines, are found on the shelves of more than 80 retail stores in Washington State. Cowlitz is Washington’s largest independent buyer of dried flower and producer of more than 2,000,000 pre-rolls annually.

There are different synergies in play here between Cowlitz and Capri that can be profitable for all parties considering GreenStar owns certain assets of Cowlitz, including IP and property leases. The details have yet to be fleshed out, but Cowlitz could become a buyer from Capri, licensee of the technology or some combination in a future deal that ensures production of high-quality, low-cost cannabis products.

Judging from initial testing, it looks like GreenStar and Progressive are onto something with the Micro Dendritic Pods. 

Supercharged Cannabinoids

Cannabinoids are components of the cannabis plant that act upon the body’s endocannabinoid system. The two most famous are CBD and THC (tetrahydrocannabinol), but there are more than 100 others that have various effects on the body. Notably, THC is the cannabinoid responsible to the psychoactive high commonly associated with ingesting marijuana.  CBD, which also can be derived from hemp – defined as cannabis sativa with less than 0.3% THC – has zero psychotropic effect.

CBD is the cannabinoid frequently heralded for a bevy of positive therapeutic effects in treating everything from dry skin to anxiety to epileptic seizures. CBD derived from hemp became legal throughout the U.S. this year with the passage of the 2018 Farm Bill.

One of the first initiatives for Capri was to complete a cultivation test using the new technology for cannabinoid analysis. In doing so, about 2,500 plants spanning three different cannabis strains were grown at Cowlitz’s facilities in Washington. The data was compelling, to say the least.

Click Here to Stay up to date with GreenStar Biosciences 

Results from independent lab tests showed total cannabinoid percentages between 22.85% to 32.54%, depending on the strain. To add some context, industry averages are generally 15%-23% for similar strains.

The strains were diverse. One had high THC content (24.54%) and lower CBD (2.24%).  Another had high CBD (22.85%) and lower THC (9.78%), while the third was virtually CBD-free (<0.01%) with high THC (25.88%).

It Doesn’t Get Any Easier Than This

In addition to a superior cannabinoid profile, the cultivation technology further demonstrated other efficiencies and benefits compared to conventional greenhouse operations. The company didn’t give away the “secret sauce,” but it did say that cultivation room was completed using “off-the-shelf” environmental control products, meaning no expensive special equipment is necessary.

This is possible, as confirmed by Washington State accredited testing facility Praxis Laboratory, without the use of pesticides, herbicides or fungicides. Moreover, Medicine Creek Analytics, a Washington State accredited heavy metal screening lab, confirmed no detectable levels of the heavy metals arsenic, lead, cadmium or mercury in the plants from the pilot run.

A drilled down look at the economics showed that electricity costs could be chopped in half, as measured by about 3 grams of plant produced from one watt of electricity versus 1-1.5 grams per watt for today’s technology.

What’s better than a cannabinoid-loaded, contaminant-free plant produced at lower operating cost per square foot?  One that grows faster. All three plant strains were harvested in 72 days, which equates to up to five harvest cycles per year. This compares to an average of three or four harvests annually for a traditional indoor grow facility.

Next Steps

“We believe we have proven the proof of concept effectiveness of this technology. We are excited to continue pursuing further testing and leveraging this proprietary technology,” said GreenStar CEO Rahim Rajwani, in a press release on the pilot testing.

The go-forward strategy involves scaling cultivation operations with the proprietary technology to lend further validation to its benefits. Capri will then use the technology for low-cost indoor production for itself and look to build an additional revenue channel through a licensing model to allow other producers, presumably including Cowlitz, access to Micro Dendritic Pods™.  

Click Here to Stay up to date with GreenStar Biosciences

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

The post Priming for Expansion, GreenStar Strikes a Deal with Progressive Herbs appeared first on CannabisFN.

PLUS Products Launches Edibles Products into Nevada Adult-Use Cannabis Market

SAN MATEO, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) — Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) (the “Company” or “PLUS”), a leading cannabis branded products company in the U.S, today announced the launch of its best-selling gummies1 into the Nevada market. The products are manufactured through the Company’s partnership with TapRoot Holdings Inc. (“TapRoot”), a vertically integrated cannabis company operating cultivation and manufacturing facilities in Las Vegas, Nevada. Commercialization comes just four months after PLUS and Taproot entered into a definitive agreement.

PLUS expands with a successful product portfolio:
PLUS is the #1 cannabis gummies brand in California with 21% market share1. PLUS has launched in Nevada with its infused-gummies product line, which includes the #1 & #2 best-selling cannabis products in California across all categories1.

Nevada is a key market for building an internationally recognized brand:
Nevada surpassed retail sales expectations in its first year of adult-use sales, and sales are expected to surpass $1.2 billion by 20222. With over 45 million visitors a year from all over the world, Nevada is a key market to building an internationally recognized brand. As in California, edible products have continued to increase in popularity, growing from 14.5% of recreational sales beginning in Q3 2017 to 18% today3.

PLUS is leading manufacturing operations to maintain quality and consistency:
TapRoot demonstrated that they are the ideal partner by providing the facilities for PLUS to easily and quickly deploy its machinery, ingredients and people to ensure that the product maintains its consistently high quality standards both in California and Nevada. PLUS intends to expand into further jurisdictions outside of California and Nevada using a similar partnership model to ensure quality and consistency across all markets.

“Operating in Nevada only four months after signing a definitive agreement with TapRoot is a testament to our commitment to execution in building a national footprint,” said Jake Heimark, co-founder and CEO of PLUS. “We have created and commercialized the best-selling gummies brand in California. Now with this expansion, we aim to replicate this successful strategy in Nevada and ensure high-quality cannabis products reach more consumers in the U.S.”

  1. Over the last twelve months by units and dollars of retail sales according to BDS Analystics
  2. Arcview Market Research & BDS Analytics: The State of Legal Marijuana Markets 6th Edition Update
  3. According to BDS Analytics

Availability

California THC: PLUS cannabis infused edibles are available in over 360 licensed retailers across the state of California.

Nevada THC: PLUS cannabis infused gummies are currently available at 3 Medmen Las Vegas locations, and are expected to be rolled out to dispensaries across Nevada in the coming weeks.

National Hemp CBD:  PLUS recently announced a line of 100% Hemp CBD infused gummies. They are available for purchase at plusproducts.com nationwide.

About PLUS

PLUS is a hemp and cannabis food company focused on using nature to bring balance to consumers’ lives. PLUS’s mission is to make cannabis safe and approachable – that begins with high-quality products that deliver consistent consumer experiences. PLUS is headquartered in San Mateo, CA with 80 employees.

For further information contact:

Jake Heimark
CEO & Co-founder
ir@plusproducts.com

Investors:

Blake Brennan
Director of Investor Relations
ir@plusproducts.com
Tel +1 213.282.6987

Media:

Bill Harrison
Third Street Media Group
bill@thirdstreetmediagroup.com
Tel +1 213.712.8811

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

This press release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (each, a “forward-looking statement”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur and include, but are not limited to, statements relating to: the retail sales expectations in Nevada; the importance of the Nevada market and its role in building an internationally recognized brand; the continued ability for TapRoot to serve as a manufacturing operations partner to PLUS and role that this partnership will play in ensuring that PLUS can maintain quality and consistency across markets; PLUS’ commitment to building a national footprint; the aim and the ability for PLUS to leverage off of the Nevada expansion to replicate its successful strategy to ensure high-quality cannabis products reach more consumers across both markets; and the expectation that PLUS cannabis infused gummies are expected to be in dispensaries across Nevada in the coming weeks.

These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this press release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the success of the Company’s investments, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of the Company’s products, customer experience and retention, the continued development of adult-use sales channels, managements estimation of consumer demand in in jurisdictions where the Company exports, expectations of future results and expenses, the availability of additional capital to complete capital projects and facilities improvements, the ability to expand and maintain distribution capabilities, the impact of competition, the ability of the Company to implement initiatives and the possibility for changes in laws, rules, and regulations in the industry. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/ff999adc-5127-491e-82c1-8f7a279e8f5e

Primary Logo

The post PLUS Products Launches Edibles Products into Nevada Adult-Use Cannabis Market appeared first on CannabisFN.

Harvest One Announces Receipt of New Cultivation Licence

VANCOUVER, Oct. 7, 2019 /PRNewswire/ – Harvest One Cannabis Inc. (“Harvest One” or the “Company“) (TSX-V: HVT; OTCQX: HRVOF), through its wholly-owned subsidiary and licensed producer United Greeneries Ltd. (“United Greeneries”), has received a cultivation licence from Health Canada for Phase I of its new Mission Road facility.

Harvest One Cannabis Inc. (CNW Group/Harvest One Cannabis Inc.)

The licence allows United Greeneries to immediately begin to cultivate cannabis in the new Mission Road facility located adjacent to the existing facility on Vancouver Island in the town of Duncan, British Columbia. Once fully completed, the Mission Road facility will triple the production capacity in Duncan and increase operational efficiency.

“The issuing of this new licence from Health Canada represents another key accomplishment for Harvest One as we continue to execute on our projects and plans to be a leading producer of premium indoor-grown cannabis,” said Grant Froese, Chief Executive Officer of Harvest One. “With our unique genetics and small batch production under the watchful eye of our first in class cultivation team, we continue to produce top tier cannabis for our discerning consumers.”

Harvest One, through United Greeneries, currently offers its premium cannabis products in four provinces for adult use consumption under the Royal High and Captain’s Choice brands. This premium cannabis is also available to medical patients direct from the United Greeneries site and through Shoppers Drug Mart under the Satipharm brand. The increased supply can also facilitate entry into additional markets for Harvest One’s brands.

About Harvest One

Harvest One is a global cannabis company that develops and provides innovative health, wellness, and selfcare products to consumers and patients in regulated markets around the world. The Company’s range of solutions is designed to enhance quality of life. Shareholders have significant exposure to the entire cannabis value chain through four wholly-owned subsidiaries: United Greeneries, a licensed producer; Satipharm (medical and nutraceutical); and Dream Water Global and Delivra (CPG), and a minority interest in Burb Cannabis (retail operations). For more information, please visit www.harvestone.com.

Cautionary Note Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. The forward-looking information contained in this press release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

The post Harvest One Announces Receipt of New Cultivation Licence appeared first on CannabisFN.

Xtraction Services Amends Lease Agreement With Puritix and Begins Invoicing Ahead of Schedule

LOS ANGELES — Xtraction Services Holding Corp., (“Xtraction Services”, “XS” or the “Company“) (CSE:XS), a fast growing provider of equipment leasing solutions to owner/operators of cannabis and hemp companies in the United States, announced today that the Company has amended its existing Lease Agreement (“Agreement’), with Puritix, LLC (“Puritix”, managed by Holistic Health, operating out of Fort Wright, Kentucky, processors of hemp biomass to produce various forms of CBD oil). The amended Agreement provides Puritix with the same yield projections at a reduced installation cost and allows Xtraction Services to invoice four (4) months ahead of schedule due to equipment availability. This modified equipment requisition reduces upfront capital requirements and frees up funds for the Company to pursue other accretive opportunities.

Highlights of Amended Agreement:

  • Revised lease terms to a fixed price per gram of crude oil as opposed to a price per gram of distillate (refined oil), reducing operational risk
  • Invoicing commenced four (4) months earlier than the original Agreement, combined with ability to invoice for crude oil produced to date (approx. US$60,000 value)

The amended Agreement provides Puritix extraction, testing and pre/post processing equipment over a term of 30 months, in exchange for a fixed price per gram of crude oil, or US$50,000 per month, whichever is greater (altered from a royalty based on a price per gram of THC free distillate). In addition, Puritix has agreed to allow Xtraction Services to invoice for crude oil already produced to date (approximately US$60,000 value). Invoicing commenced this month, four (4) months earlier than originally anticipated.

David Kivitz, Chief Executive Officer of XS, commented, “The amended Agreement is a win-win for both parties. We are proud to work with a leading extraction company like Puritix and will continue to support their team so that they can meet their business objectives.”

“The cannabis and hemp industries are in constant flux and we are well-positioned to meet the unique and changing demands. As well, the modified equipment needs allowed us to free up capital to pursue additional opportunities. We look forward to providing periodic updates on our initiatives moving forward.”

Christopher D. Stock, Chief Executive Officer of Puritix, LLC commented, “The team at Xtraction Services has been very supportive throughout this process. The revised terms give us the flexibility to produce a full spectrum of products to better serve the needs of our customers. We will be working closely with the Xtraction Services team going forward and expect to be ramping up our production, moving from our current one shift per day on a four-day schedule, to a 24/7 schedule by the end of November.”

About Xtraction Services

Founded in 2017, XS specializes in providing equipment leasing solutions in the United States to owner/operators of cannabis and hemp companies, including cultivators, oil processors, manufacturers, testing laboratories, among others. In addition, XS provides a full range of consulting services including equipment selection and procurement, through its network of preferred vendor partnerships with original equipment manufacturers and equipment distributors. Further, XS also provides a full range of all on-site support services including staff recruitment, process development, and product formulation. This powerful dynamic provides an end-to-end solution for customers which results in recurring revenues, strong profit margins, and a proven business model for XS stakeholders.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This press release contains “forward-looking information” and may also contain statements that may constitute “forward-looking statements”, collectively “forward-looking information”, within the meaning of applicable Canadian securities legislation. Such forward-looking information is not representative of historical facts or information or current condition, but instead represent the beliefs and expectations regarding future events about the business and the industry and markets in which Xtraction Services operates, as well as plans or objectives of management, many of which, by their nature, are inherently uncertain. Generally, such forward-looking information can be identified by the use of terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking information contained herein may include but is not limited to: final installation costs and timing of installation of newly leased equipment; and actual dollar value of product produced to date.

Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Accordingly, readers should not place undue reliance on forward-looking statements, which are qualified in their entirety by this cautionary statement. Xtraction Services does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

This press release does not constitute an offer to sell nor a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. newswire services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. securities laws.

logo

Contacts

David Kivitz
Chief Executive Officer

Antony Radbod
Chief Marketing Officer

Tel: 1-407-900-4737 Ext. 5
Email: ir@xtractnow.com
www.xtractnow.com

The post Xtraction Services Amends Lease Agreement With Puritix and Begins Invoicing Ahead of Schedule appeared first on CannabisFN.

GABY to Acquire Premium Organic CBD Brand 2Rise Naturals

SANTA ROSA, CALIFORNIA and CALGARY, ALBERTA / ACCESSWIRE / October 2, 2019 / GABY Inc. (“GABY” or the “Company“) (CSE:GABY)(OTCQB:GABLF), a U.S.-focused California based consumer packaged goods (“CPG”) company operating in both the regulated cannabis sector and in the hemp-derived CBD market in the mainstream grocery channel, announced today that the Company has signed a definitive agreement to acquire all issued and outstanding securities of 2Rise Naturals LLC, (“2Rise“) in an all-share transaction valued at USD$1 million (the “Transaction“). The proposed transaction will enhance GABY’s portfolio of CBD products and is a natural fit with GABY’s current portfolio of CBD products, LuLu’s Chocolate and the Sonoma Specific CBD skincare line. 2Rise has gained market popularity for its transparency in sourcing and only using top-quality certified organic ingredients. 2Rise’s promises customers 100% plants, no chemicals.

Highlights

  • 2Rise owns a portfolio of high-quality organic CBD products including, THC-Free CBD tincture, full-spectrum tincture with turmeric or vanilla, and high potency full spectrum capsules. 2Rise products are focused on the CBD supplement market and complement GABY’s existing CBD line Lulu’s Chocolates and Sonoma Specific skincare line.
  • 2Rise products are distributed in 100 stores nationwide, including high-end California health food chain Erewhon. GABY expects to be able to rapidly expand distribution through GABY’s existing mainstream distribution.
  • 50% of 2Rise sales are direct retail via their website and are heavily driven by repeat customers.

“2Rise is the perfect example of our acquisition framework. A reputable brand that has shown high customer loyalty with strong repeat customer purchases that we can rapidly grow by introducing to a wider customer base using our developed mainstream and regulated sales channels,” said Margot Micallef, founder and CEO of GABY “Kendra has done a tremendous job creating a product that resonates with customers by always delivering on the 2Rise promise of high-quality 100% organic plant-based products. We look forward to carrying on that promise and introducing it to a much wider group of customers.”

“We’ve been able to grow 2Rise organically, doubling sales each year for the last three years without any incremental growth capital. We decided to join GABY because of their access to a wide network of mainstream retailers eager to sell high-quality, all-natural CBD products and the wealth of experience they have working in the health and wellness space,” said Kendra Mark, founder of 2Rise. “It is time to take 2Rise to the next level, bring the product to thousands of new customers who are eager to take control of their health.”

Transaction Terms

GABY propose to acquire all issued and outstanding securities of 2Rise in an arm’s length transaction on the basis of common shares of GABY being issued to the holders of 2Rise securities in exchanged for all issued and outstanding 2Rise securities based on GABY share price calculated based on the 5-day volume-weighted average trading price (“VWAP“) prior to and including the date of the announcement of the Transaction at an enterprise value of USD$1.0 million in respect of 2Rise.

As part of the Transaction GABY will issue 500,000 warrants giving the holder of the warrant for a period of two years the right to purchase 500,000 GABY common shares at a price of $0.45.

The closing date for the purchase of 2Rise by GABY shall be on or about October 30, 2019.

About GABY Inc.

GABY is a U.S.-focused, consumer packaged goods company operating a family of brands in the cannabis industry and in the mainstream grocery channel. Through its subsidiaries GABY indirectly holds a number of licenses and permits issued by the California Department of Health, the California Bureau of Cannabis Control and the County of Sonoma respectively, including manufacturing, distribution, cultivation and nursery licenses. With these licenses and permits to operate in the cannabis channel, and its existing infrastructure of major retailers and an extensive broker and distribution network in the mainstream channel, GABY has successfully brought a number of its proprietary, acquired and third-party brands to market in both the licensed and mainstream market.

Margot and her sister Gabriella co-founded GABY after Gabriella received a dire cancer diagnosis which spurred the sisters to prolong Gabriella’s life through a holistic approach to health. Today, GABY is a wellness company with a diverse range of products that use cannabis, hemp and hemp-derived cannabinoids to address a variety of dietary and health concerns. Although Gabriella ultimately passed away from her illness, she lived exponentially longer than doctors predicted. Her memory and passion live on through GABY’s mission: to empower people to live healthy lives without compromise.

GABY’s shares trade on the CSE under the symbol “GABY” and on the OTCQB under the symbol “GABLF”. For more information, visit www.GABYInc.com

For further inquiries, please contact:

General

Margot Micallef, Founder & CEO or Investor Relations at IR@GABYINC.com or 800-674-2239.

Investors
Mark Kuindersma, CFA
LodeRock Advisors Inc.
mark.kuindersma@loderockadvisors.com
(416) 465-6931

Media
Colin Trethewey, APR
colin@prmedianow.com
813-480-1354.

Disclaimer and Forward-Looking Information

The CSE does not accept responsibility for the adequacy or accuracy of this release. Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, certain of which are beyond the control of the Company. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Forward-looking statements include, but are not limited to, the anticipated closing of the Transaction,, the continued growth and expansion of the Company’s operations, and the receipt of regulatory approvals, including the approval of the CSE. The Company assumes no obligation to update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Each of KJM Data and Research Inc., and Sonoma Pacific are subsidiaries of GABY. Each of these subsidiaries hold cannabis licenses in the State of California. Unlike in Canada which has Federal legislation uniformly governing the cultivation, distribution, sale and possession of medical cannabis under the Cannabis Act (Federal), readers are cautioned that in the United States (“U.S.“), cannabis is largely regulated at the State level. Cannabis is legal in the State of California however cannabis remains illegal under U.S. federal laws. Notwithstanding the permissive regulatory environment of cannabis at the State level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act in the U.S. and as such, cannabis-related practices or activities, including without limitation, the manufacture, importation, possession, use or distribution of cannabis are illegal under U.S. federal law. To the knowledge of the Company, the businesses operated by each of GABY’s subsidiaries are conducted in a manner consistent with the State law of California and are in compliance with regulatory and licensing requirements applicable in the State of California. However, readers should be aware that strict compliance with State laws with respect to cannabis will neither absolve GABY, or its subsidiaries of liability under U.S. federal law, nor will it provide a defense to any federal proceeding in the U.S. which could be brought against any of GABY, or its subsidiaries. Any such proceedings brought against GABY, or its subsidiaries may materially adversely affect the Company’s operations and financial performance generally in the U.S. market specifically.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE: GABY Inc.

The post GABY to Acquire Premium Organic CBD Brand 2Rise Naturals appeared first on CannabisFN.

FluroTech Provides Biotracker Update and Proposes Unique Solution to Ascertain Legal From Illicit Vape Cartridges

CALGARY, Alberta, Oct. 02, 2019 (GLOBE NEWSWIRE) — FluroTech Ltd. (TSX-V: TEST) (OTCQB: FLURF) (“FluroTech” or the “Company”), an aspiring leader in analytical cannabis and hemp testing technologies, announces that, in order to test the performance of its biotracker technology outside of the laboratory, company scientists introduced the technology to numerous hemp plants in its outdoor beta testing sites. The plants from the beta testing sites have now been harvested and FluroTech is pleased to announce that initial results appear to show that the harvested plants’ root systems did take up the biotrackers and dispersed throughout the plant.

The Company is excited by these initial preliminary results and believes that its biotracker technology, once it is ready for commercialization, has the potential to address several issues facing the cannabis industry today, provided that it continues to perform as currently anticipated by the Company.  For example, such technology may be applied to specifically label extract in vape cartridges to allow government officials and intermediaries along the supply chain to identify legally produced vape cartridges from those produced illegally. This is particularly relevant in the current market, given the recent negative publicity surrounding illness and deaths from vaping, which may be caused by illicit cannabis vape cartridges containing various contaminants.

In addition, notwithstanding manufacturers’ best efforts, FluroTech notes that there are still some vulnerabilities in the supply chain where illegal product could enter the legal system, for example by employing forged packaging. The use of a biotracker, introduced into the flower and then carried through the extraction process into the extract, may be a potential solution to this vulnerability, as the biotracker could then be verified using the Company’s CompleTestTM process.

“FluroTech is continually exploring unique ideas to solve issues plaguing current seed-to-sale in this nascent industry. Our primary goal is to help the legal participants in the cannabis and hemp industry differentiate their product from that produced in the illicit market,” stated Danny Dalla-Longa, Chief Executive Officer at FluroTech. “The FluroTech development team continues to progress its biotracker technology as the Company continues to explore partnerships to effectively scale the technology, which could ultimately allow for validation along the entire supply chain.”

About FluroTech (TSX-V: TEST) (OTCQB: FLURF)

FluroTech is a technology and marketing company whose core business is focused on the commercialization of new technologies in the cannabis industry. FluroTech’s proprietary spectroscopy-based technology allows for the testing and identification of organic and inorganic compounds contained within biological samples. Using the technology that was developed at the University of Calgary, FluroTech has developed a two-part solution comprising an instrument called the CompleTest™ and consumable testing kits.

To learn more, visit www.FluroTech.com.

Contact Information

Danny Dalla-Longa
Chief Executive Officer
403.680.0644
danny@flurotech.com

FluroTech Ltd.
Alistair Ross Technology Centre
Suite 111, 3553-31 Street NW
Calgary, AB T2L 2K7
info@flurotech.com

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or the securities laws of any state and may not be offered or sold within the United States or to or for the benefit or account of U.S. persons, absent such registration or an applicable exemption from such registration requirements.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of Canadian securities legislation. Forward-looking information generally refers to information about an issuer’s business, capital, technology or operations that is prospective in nature, and includes future-oriented financial information about the issuer’s prospective financial performance or financial position. The forward-looking information in this news release includes disclosure about the commercialization of the Company’s biotracker technology and timing thereof, the potential uses of the biotracker technology and the benefits thereof and the anticipated performance of the Company’s biotracker and CompleTestTM technologies.

The Company made certain material assumptions, including but not limited to prevailing market conditions and general business, economic, competitive, political and social uncertainties, the need and demand for the CompleTestTM and biotracker technology in the cannabis and hemp industry and the potential uses of the biotracker technology, to develop the forward-looking information in this news release. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Actual results may vary from the forward-looking information in this news release due to certain material risk factors. These risk factors include, but are not limited to, adverse market conditions and regulatory and other risks associated with the cannabis and hemp industries in general, users of the Company’s the CompleTest™ failing to achieve the anticipated benefits of the product, competition from other developers of similar technology , failure to reach commercialization of the technology and failure for the products anticipated market to develop. The Company cautions that the foregoing list of material risk factors and assumptions is not exhaustive.

The Company assumes no obligation to update or revise the forward-looking information in this news release, unless it is required to do so under Canadian securities legislation.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release.

Primary Logo

The post FluroTech Provides Biotracker Update and Proposes Unique Solution to Ascertain Legal From Illicit Vape Cartridges appeared first on CannabisFN.

Nabis Holdings Provides Shareholder Update and Reports Third Quarter 2019 Financial Results

Strengthened management team with the appointment of Nicole Rusaw as Chief Financial Officer

Cash and cash equivalents of CAD$20.3 million as of July 31, 2019

VANCOUVER, British Columbia, Oct. 02, 2019 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE:NAB) (OTC: NABIF) (FRA: A2PL) (“Nabis™” or the “Company”), a leading Canadian investment company with specialty investments in assets across multiple divisions of the cannabis sector, reported its financial results for the third quarter ended July 31, 2019. All financial information is provided in Canadian dollars unless otherwise indicated.

“We continue to make progress on our strategic plan by diligently working on and closing acquisitions in Arizona, California, Michigan and Washington. In Arizona, we successfully acquired a 44,000 sq ft cultivation, fulfillment and production facility to serve as our hub of operations. With a definitive agreement signed on a Phoenix, AZ based dispensary along with a manufacturing & supplier agreement in AZ for WISP, a unique vaporizing solution, we are excited about the opportunity for Nabis in this state,” said Shay Shnet, CEO and Director of Nabis.

“We are pleased to report a strong balance sheet with a cash balance that will fund us through our previously announced acquisitions. As we focus on driving our business forward, yesterday we announced a strategic new hire to strengthen our management team. Nicole Rusaw joins Nabis as our Chief Financial Officer as an experienced public company leader with a proven track record. With our enhanced leadership at the helm, we look forward to reaching many milestones performance on our strategic initiatives,” concluded Mr. Shnet.

Third Quarter 2019 Highlights and Subsequent Events

Expanded U.S. Footprint

  • Arizona: In September, the Company acquired a 44,000 sq. ft. cultivation, fulfillment and production facility located in Camp Verde, Arizona near Phoenix. This facility will serve as the hub of Nabis’ operations. In August, the Company signed a definitive agreement to acquire a licensed medical marijuana business including a Phoenix dispensary.
  • California: In June, the Company signed a definitive agreement to acquire Desert’s Finest, a 6,000 sq ft dispensary located in Desert Hot Springs, California. Nabis announced yesterday  improved terms to the acquisition agreement; press release can be found here.
  • Washington: In May, the Company purchased an established extraction and production facility.

Growing Brand Portfolio

  • Launched BIS (Be In Synergy), a new CBD exclusive brand created and owned by Nabis.
  • Announced strategic alliance with CannaKorp, Inc. for its Wisp Vaporizing System as an authorized manufacturer and supplier of Wisp Pods in Arizona.
  • Acquired a 49% stake in Cannova Medical, an Israeli based company and developer of the sublingual strip, an alternative method for cannabis consumption.

Experienced Leadership Team

  • Appointed Nicole Rusaw as Chief Financial Officer, effective October 1, 2019.
  • Announced industry veteran, Emmanuel Paul as an Independent Director in August 2019.

Capital Markets

  • In May, Nabis secured DTC Eligibility for its shares listed on the OTC, improving the trading process in the U.S.

Financial Results for the Third Quarter Ended July 31, 2019

Net loss for the third quarter of 2019 was $5.2 million compared to a net loss of $0.06 million in the third quarter of 2018.

Balance Sheet and Liquidity

As of July 31, 2019, the Company had total assets of $44.6 million, including cash and cash equivalents of $20.3 million and a working capital position of $19.5 million.

As of October 1, 2019, there were 109,604,435 shares of common stock outstanding.

About Nabis Holdings Inc.
Nabis Holdings is a Canadian investment issuer that invests in high quality cash flowing assets across multiple industries, including real property, securities, cryptocurrency, and all aspects of the U.S. and international cannabis sector. Led by two of the co-founders of MPX Bioceutical, one of the largest takeovers in the U.S. Cannabis space to date, the company has a proven track record in emerging markets to create significant shareholder value. The Company is focused on investing across the entire vertically integrated aspects of the space with a focus on revenue generation, EBITDA and growth.

For more information, please visit https://www.nabisholdings.com/.

Forward-Looking Statements
All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The risks are without limitations: that the acquisitions will be completed by the Company or completed upon the terms disclosed; the price for cannabis and related products will remain consistent and the consumer demand remains strong; availability of financing to the Company to develop the retail locations; retention of key employees and management; changes in State and/or municipal regulations of retail operations and changes in government regulations generally. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission and the Alberta Securities Commission.

For inquiries, please contact:

Investor Contact:
Allison Soss
KCSA Strategic Communications
PH: 212-896-1267
Nabis@kcsa.com

Company Contact:
Shay Shnet, CEO and Director
PH: 905-581-5521 x107
info@nabisholdings.com

Primary Logo

The post Nabis Holdings Provides Shareholder Update and Reports Third Quarter 2019 Financial Results appeared first on CannabisFN.